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Abstract 
 
Telomeres play significant roles in maintaining genome stability, regulating cell proliferation 
and apoptosis. The role of telomere biology and telomerase reactivation has been studied 
extensively in cancers. Telomerase has been previously associated with driving chronic kidney 
disease (CKD) advancement and most frequently due to HIV infection. However, the 
mechanism by which telomerase activation contributes towards disease progression beyond 
its canonical function of telomere maintenance is poorly understood. Telomerase is a 
ribonucleoprotein whose main function is telomere maintenance. Telomerase activity is 
dependent on expression of the rate-limiting human telomerase reverse transcriptase 
(hTERT) component. In addition to telomere maintenance, hTERT is implicated in other non-
telomere related functions that promote cellular proliferation. Expression of hTERT is 
predominantly regulated at the transcription level where variation in promoter and 
minisatellite (MNS16A) sequences alter its expression.  This variation has been implicated to 
confer susceptibility to diseases such as cancer and ageing disorders in non-African 
populations. Data on variation and pathogenicity of telomere-associated genes in African 
populations is limited and warrants further research. Thus bioinformatics analysis was 
performed to elucidate variation within the human TERT gene and promoter in different 
populations. The promoter, MNS16A and relative telomere length (RTL) were also evaluated 
in 159 African study participants with and without CKD. TERT common variants are equally 
distributed across populations with limited data on connection to the effects of the variants 
in African populations. Further bioinformatics analyses revealed significant difference 
(p<0.0001) in distribution of promoter variant rs2853669 between African and non-African 
populations. No common promoter mutations were identified in our study population. 
Interestingly, the long MNS16A variant suggested to increase TERT expression was 
significantly overrepresented in individuals with CKD regardless of HIV status. For the first 
time, a strong association of the long MNS16A variant with CKD regardless of HIV status is 
reported, implicating MNS16A as a potential risk factor in CKD. 
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Chapter 1: Literature Review/Introduction 
1.1. Background to the study 
Human immunodeficiency virus (HIV) is still one of the leading causes of death in Africa (Sharp 
and Hahn, 2011). Ever since the emergence of HIV many diseases have become common and 
have been shown to be familiarly associated with HIV infection. Chronic kidney diseases (CKD) 
continue to be important determinants of morbidity and mortality in both HIV infected and 
uninfected individuals (Gupta et al., 2005). Telomeres and telomerase have been implicated in 
driving kidney disease progression especially in the presence of HIV infection (Shkreli et al., 
2012). The introduction below highlights the relevance of telomere biology in kidney disease. 
However there is limited data regarding the role of telomeres and telomerase in disease 
progression and severity. Thus emphasizing the need of this study to assess telomere and 
telomerase genetics as potential biomarkers in kidney disease.  
1.2. Human Immunodeficiency Virus 
 
1.2.1. What is HIV? 
HIV is a virus that causes Acquired Immunodeficiency Syndrome (AIDS). HIV has spread all over 
the world and has caused one of the deadliest pandemics in human history since its discovery in 
the 1980s (Barre-Sinoussi et al., 1983; Duesberg, 1988; Gallo et al., 1984). HIV is a retrovirus 
distinguished by its slow persistent replication (Gendelman et al., 1985). HIV has the ability to 
infect the immune system cells whose function is to protect the body against any foreign 
infectious molecules (Ho et al., 1988). This causes the immune system to fail and thus weakens 
the body and increases susceptibility to life-threatening infections. Destruction of the immune 
system, the main characteristic of the disease, causes patients to die from a range of 
opportunistic infections. As the opportunistic infections that occur reflect the prevalence of 
given pathogens in the afflicted population, tuberculosis has been one of the most common 
outcomes in Africa (Corbett et al., 2003; Girardi et al., 1997; Raviglione et al., 1997). 
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1.2.2. HIV: epidemiology, treatment and related diseases 
Although HIV/AIDS has been recognised as a global epidemic, Africa still has the highest rates. 
The 2015 AIDS global epidemic report statistics released by the UNAIDS has revealed that Sub-
Saharan Africa accounts for 70% of global HIV infections even though it has only 10% of the 
global population (http://www.unaids.org). This shows that the burden of HIV in this area is 
enormous. Moreover, in 2013 alone, South Africa had the second highest AIDS related deaths 
globally after Nigeria (Fig. 1).  
 
The HI virus has different subtypes represented in two major groups namely; HIV type one (HIV-
1) and type two (HIV-2). HIV-1 is the most common and pathogenic strain of the virus. Unlike 
HIV-1; HIV-2 is less pathogenic and is mostly found in West Africa (Gnann et al., 1987). The HIV-
1 strain has several subtypes classified as HIV-1 subtypes A to K. Subtype C is the most common 
HIV strain in sub-Saharan Africa, India and Somalia. In Europe and America, subtype B and 
others are in high prevalence (Gnann et al., 1987).  
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Figure 1: Chart showing the global AIDS related deaths with South Africa accounting for 13%, the second 
highest death rate in the world. Image obtained from the UNAIDS 2013 global report on the AIDS 
epidemic http://www.unaids.org (Accessed 03 March 2015). 
 
HIV is not curable but can be managed by highly active antiretroviral treatment (HAART). These 
therapies combine inhibitors of the HIV protease and reverse transcriptase to slow down the 
viral progression (Autran et al., 1997). Although HIV-1 antiretroviral drugs were intended to 
treat the most common subtype in Europe and America, subtype B, they are currently used to 
treat subtype C. There has been limited evidence suggesting that these drugs are less effective 
on other HIV subtypes.  
Despite the use of anti-retroviral drugs many diseases are still associated with HIV (Cohen, 
2007). These diseases range from basic genital thrush to severe complex diseases such as 
cancer. Diseases that involve kidney malfunction have also been recognised as important 
susceptibility factors that lead to end stage renal disease (ESRD), a permanent state of kidney 
malfunction. ESRD is a severe major cause of death in HIV positive patients presenting with 
kidney disease (Rao et al., 1984). This has resulted in an increased burden of chronic kidney 
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disease in areas mostly affected by the HIV epidemic such as Sub-Saharan Africa (Fabian and 
Naicker, 2009; Naicker, 2010).  
1.3. The Kidney  
1.3.1. HIV and the Kidney 
In 1984, a team of scientists described HIV-1–seropositive individuals who presented with renal 
disorder portrayed by gradual renal malfunction and proteinuria accumulation in their kidneys 
(Rao et al., 1984). However, many argued that the features were similar to those of renal failure 
caused by drug abuse such as heroin (Mazbar et al., 1990). Further studies were undertaken 
which revealed similar renal disease features in HIV patients with no drug abuse history 
(Bourgoignie et al., 1988). 
 
Since then, it was shown that with HIV infection, patients develop an increased risk of acquiring 
acute, chronic and end-stage kidney disease. Furthermore, individuals of African ancestry have 
been shown to have four-fold increased risk of developing kidney disease compared to 
Caucasians (Naicker, 2010). The risk increases 18 to 50 fold in the presence of HIV infection 
(Fabian and Naicker, 2009; Fabian et al., 2013; Wyatt et al., 2007). These kidney diseases 
include thrombotic microangiopathy, immune complex-mediated glomerulonephritides, HIV-
associated nephropathy (HIVAN) etc (Naicker, 2003, 2009). HIV infection is one of the common 
causes of chronic renal disease in HIV-1 infected individuals (Rao et al., 1984;(Winston et al., 
1999). HIVAN, the severe form of CKD, is the third leading cause of end-stage renal disease 
(ESRD) in African Americans between the ages of 20 and 64 years (Winston et al., 1999). 
It has also been indicated that the presence of opportunistic viral infections such as HIV could 
contribute to renal disease. The interaction of HIV proteins with renal cells such as that of the 
glomerulus and podocytes, direct infection of HIV-1 in renal cells as well as expression of HIV 
genes in kidneys (Fabian et al., 2013; Naicker, 2009, 2010; Wyatt et al., 2007). In addition, HIV 
infection has also been suggested to alter the expression of certain genes including the 
telomerase reverse transcriptase (TERT) gene which plays a role in kidney disease severity and 
progression (Chugh and Clement, 2012; Shkreli et al., 2012). 
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1.3.2. Chronic Kidney Disease (CKD) 
Chronic kidney disease (CKD) is an umbrella term used to describe various disorders involving 
the disruption of the structure and function of the kidney (Levey and Coresh, 2012; Levey et al., 
2003). The discrepancy in disease expression is related to cause and pathology, severity and 
rate of progression. CKD has become a worldwide public health problem. In the United States 
alone, the occurrences of kidney malfunction are rising. Similarly, developing countries in sub-
Saharan Africa are also experiencing higher rates of CKD resulting in poor renal health 
outcomes and high costs of treatment (Naicker, 2003, 2009). Consequences of chronic kidney 
disease include not only kidney failure but also complications in heart health leading to 
cardiovascular disease. Existing evidence indicates that some of these adverse outcomes can be 
prevented or delayed by early detection and treatment. Unfortunately, CKD is under-diagnosed 
and undertreated in sub-Saharan Africa, in part as a result of lack of research identifying 
possible risk factors and treatment options (Kopp et al., 2010; Naicker, 2009, 2010). 
1.3.2.1. Characteristics of CKD 
 
Figure 2: The renal corpuscle of the kidney showing the glomerular capillaries and the podocytes 
wrapped around them. The image shows an illustration of a normal kidney renal corpuscle. Image was 
adapted from Kidney and Urinary Tract Histology Study Guide accessed through 
http://www.siumed.edu/~dking2/crr/rnguide.htm (Accessed 30 April 2014). Image reproduced with 
permission from Professor David King (Southern Illinois University, Carbondale). 
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One mechanism in which CKD can arise is through podocyte malfunction. Podocytes are 
terminally differentiated epithelial cells that are located inside the glomerulus (Barisoni and 
Mundel, 2003; Mundel and Kriz, 1995; Zhu et al., 2013). They contribute to the formation of an 
intact glomerular barrier and their main functions include maintenance of glomerular 
capillaries, creation of glomerular basement membrane and regulation of glomerular filtrations 
(Barisoni et al., 2000; Barisoni et al., 1999). Podocytes normally leave gaps or thin filtrations 
allowing regulation of the filtration barrier (Fig. 2).  
Podocyte proliferation is dependent on their state of differentiation. As they mature, they 
acquire a terminally differentiated phenotype (Nagata et al., 1998) i.e. they reach their finite 
ability to replicate. This maturation is accompanied by loss of proliferative activity and 
expression of Wilms tumor gene, WT1 a gene responsible for signalling cell maturation.    
Podocytes are injured in many forms of glomerular malfunctions due to diseases that involve 
the immune system, toxin and metabolism associated injury and viral infection (Barisoni et al., 
2000). Due to their restricted ability to proliferate, podocytes generally cease dividing and die 
out in most glomerular diseases resulting in glomerulosclerosis, a condition where filtration 
barrier is lost due to accumulation of fibrous scar tissue (Mundel and Kriz, 1995). However, 
studies have shown that in glomerular diseases that are idiopathic and those associated with 
HIV infection, podocytes lose their maturity and undergo dedifferentiation and re-enter the cell 
cycle causing interference within the filtration barrier (Barisoni et al., 2000).  This interference 
results in glomerular collapse, a condition were renal epithelial cells over proliferate and cause 
renal structure abnormalities.  
1.3.2.2. Pathogenesis of CKD 
Patients with CKD usually present with proteinuria, a condition where there is an unusual 
amount of albumin in the urine, and reduced renal function (Klotman, 1999). Presence of renal 
tubular epithelial cells in the urinary residue and high levels of serum creatinine also indicate 
gradual loss of kidney function (Klotman, 1999). Hypertension is also common among most 
patients (Go et al., 2004). 
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1.3.2.3. Epidemiology of CKD 
In the 2010 Global Burden of Disease,  CKD was listed as the 18th among the diseases that cause 
death globally. In fact, according to the World Health Organisation (WHO), CKD escalated nine 
places up in the list from 27th in 1990.  It is estimated that the prevalence of CKD ranges 
between 16 –18 % globally (Couser et al., 2011). The prevalence and incidence of CKD varies 
substantially in different regions or countries. For example, in the United States alone, 26 
million individuals are estimated to suffer from CKD (Coresh et al., 2007; Couser et al., 2011). In 
sub-Saharan Africa, the overall estimated prevalence is 13.9% ranging from 2% in Ivory Coast to 
30% in Zimbabwe and 14.3% in South Africa (Jha et al., 2013).  There are different types of CKD 
which can vary according to pathological abnormalities of the kidney, proteinuria levels and 
estimated glomerular filtration rate (eGRF). These different types of CKD include thrombotic 
microangiopathy, immune complex-mediated glomerulonephritides (HIVICK) and HIV-
associated nephropathy (HIVAN) (Naicker, 2003, 2009). The prevalence of these diseases 
differs. In fact a study performed on 99 biopsies from HIV seropositive patients presenting with 
kidney disease by the nephrology unit at Chris Hani Baragwanath Hospital, Johannesburg South 
Africa revealed that most of these patients (27%) presented with HIVAN, a severe type of CKD 
(Fig. 3). HIVAN shows a major increased tendency for HIV-infected individuals with African 
origin compared to other races (Abbott et al., 2001). However the current epidemiology of its 
prevalence in Africa is largely unknown due to under developed facilities.  
1.3.2.4. Risk factors 
The molecular mechanisms of CKD are poorly understood. Although considerable evidence 
indicates environmental factors as important role players in CKD progression, these do not 
completely explain the heterogeneity observed in CKD aetiology (Laouari et al., 2011). Disparity 
in CKD progression among individuals exposed to similar risk factors has been observed. 
Although non-communicable diseases such as Diabetes mellitus, obesity and hypertension are 
well-known triggers of CKD in developed countries (Coresh et al., 2007). In addition, in Asian 
and some sub-Saharan African countries, acute inflammation of the kidney and unknown 
triggers are recognised as major causes (Jha et al., 2013). Furthermore, rapid urbanisation and 
globalisation are believed to have accelerated the transition in disease burdens. Together with 
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continued high prevalence of infectious diseases and an increasing prevalence and severity of 
lifestyle disorders, such as diabetes and hypertension. In developing countries including South 
Africa incidences of CKD have increased over the years (Naicker at al., 2009).  
 
Figure 3: The prevalence of renal disease in HIV-positive patients biopsied between 2003 and 2004 at 
the Chris Hani Baragwanath Hospital (Gerntholtz et al., 2006). The most common CKD observed in HIV 
positive individuals was HIVAN accounting for 27% of CKD cases. Image reproduced with permission 
from the Nature Publishing Group. 
Furthermore, ethnic differences have been detected in CKD progression suggesting that genetic 
factors may also contribute to susceptibility (Kopp et al., 2010; Laouari et al., 2011; Naicker, 
2010). In the 1980s kidney diseases such as HIVAN was noticed mostly among African-
Americans and Haitian immigrants in the United States (US). These findings suggested a strong 
racial discrepancy and genetic susceptibility that characterizes this distinctive kidney disease 
(Wyatt et al., 2012). Whilst several studies have investigated genetic components that confer 
susceptibility to CKD, the gene variants predisposing individuals to CKD are largely unknown. In 
fact, a strong association of the myosin gene MYH9 and nephropathy was observed in African 
American individuals suffering from nephropathy (Kopp et al., 2008).  Despite the compelling 
association of MYH9 gene to HIVAN, several significant concerns remained ambiguous. One of 
which was the presence of the homozygous risk allele in one third of the African-American 
healthy individuals, suggesting that there were other genetic and environmental factors that 
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contribute to susceptibility to disease (Kopp et al., 2008). Further studies were performed to 
assess the susceptibility locus on chromosome 22q13.1. A stronger association was discovered 
with the apolipoprotein 1 gene (APOL1) (Genovese et al., 2010). Two APOL1 significant alleles 
were only identified in African participants who were part of the 1000 Genomes Project and 
these were shown to be in strong linkage disequilibrium with the MYH9 risk allele (Genovese et 
al., 2010; Wyatt, 2012). Furthermore, variation in MYH9 and APOL1 has been shown to be 
associated with non-diabetic chronic kidney disease in individuals of African origin with a 
significant association of APOL1 risk alleles in black South Africans (Kasembeli et al., 2015).  
More studies in mice have emphasised the role of genetic factors in CKD. In fact, a study by 
Shkreli and colleagues (2002) has shown that transgenic expression of the telomerase reverse 
transcriptase (TERT) in mice induced glomerular collapse resembling that in human CKD (Fig. 4). 
In contrast, silencing TERT in HIVAN mice models resulted in controlled podocyte proliferation 
and improved filtration barrier (Shkreli et al., 2012). This was an interesting finding as TERT has 
been previously implicated in disease involving de-differentiation and proliferation of cells 
(Gordon and Santos, 2010; Nakayama et al., 1998; Sekhri, 2014; Shay and Wright, 2001a). These 
findings further warranted an investigation of the role of telomerase in CKD. 
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Figure 4: Mechanism of glomerular collapse caused by upregulation of TERT. The image illustrates the 
suggested mechanism by which HIV and non-HIV infections can induce up-regulation of TERT and the 
Wnt/β-catenin pathway. This inturn induces epithelial cell proliferation in the glomerulus resulting in 
glomerular collapse. Image obtained from (Chugh and Clement, 2012).    
1.4. Telomere, Telomerase and Disease 
 
One distinct feature observed in CKD is the proliferation and dedifferentiation of podoctyes 
leading to the glomerular collapse (D'Agati et al., 1989). In order to understand the ability of 
podocytes to dedifferentiate and re-enter cell cycle in CKD, pathways involved in cell 
proliferation need to be studied. One well defined pathway previously implicated in unlimited 
cellular proliferation is the telomerase reactivation (Shay and Bacchetti, 1997; Shkreli et al., 
2012). Telomerase is an enzyme whose functions include regulation of cellular proliferation and 
viability. Exploring the role of telomere biology in CKD will help understand the pathogenesis of 
disease and ultimately allow identification of potential drug targets for the treatment or 
management of CKD. This will possibly improve renal health outcomes.  
 
 
17 
 
1.4.1. Telomeres and telomerase 
1.4.1.1. Telomeres 
Telomeres are DNA-protein complexes found at the end of eukaryotic chromosomes 
(Blackburn, 2000). Telomeres are composed of double-stranded (ds) and single-stranded (ss) G-
rich DNA tandem repeats (TTAGGG in mammals) (Fig. 5). Telomeres are responsible for capping 
the ends of chromosomes, thus play a protective role as they prevent loss of essential genetic 
sequences (Chan and Blackburn, 2004). Telomeres achieve this through counteracting the 
effects of exonuclease activity and the “end-replication problem” i.e. without telomeric 
repeats; gene coding sequences would be lost (Wellinger et al., 1996).  
Telomeres are bound by several telomeric proteins called the “Shelterin” complex (de Lange, 
2005). This complex interacts together with several factors associated with DNA repair to alter 
the structure of the telomeric DNA (de Lange, 2005) (Fig. 6). This alteration allows protection of 
single-stranded telomeric DNA from events such as exonuclease activity, end-to-end fusion 
(Letsolo et al., 2010; Lin et al., 2010) with other telomeres and/or with broken DNA strands and 
unsuitable recombination (Plohl et al., 2002).  
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Figure 5: Diagram showing dsDNA and ssDNA repeats of terminal ends of eukaryotic chromosomes 
called telomeres. Image obtained from Pharminox accessed through 
http://www.pharminox.com/telomere_signalling.aspx.  
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Figure 6: Diagram showing telomere DNA-protein complex and its formation. Proteins such as the 
protection of telomeres 1 (POT1) and Dyskerin (DKC1) are recruited to stabilise telomeres by forming a 
structure called the T-loop. Image obtained from O’Sullivan and Karlseder (2010).  
Without the formation of the Shelterin complex, detrimental consequences that may lead to 
genomic instability may arise (O'Sullivan and Karlseder, 2010).  These processes are potentially 
catastrophic; for example, fusions can lead to the formation of dicentric chromosomes, which 
are inherently unstable and result in imbalances in the genetic content of dividing cells 
progeny, or to a loss of genetic information (Artandi and DePinho, 2010; Letsolo et al., 2010; Lin 
et al., 2010).  
To combat the loss of telomeric repeats, the shelterin complex not only works with DNA repair 
factors but also helps in recruiting the telomerase enzyme which is responsible for synthesis of 
telomeric DNA and counteracting the “end-replication problem” (section 1.4.1.2) (de Lange, 
2005). In addition, telomeres also associate with several proteins to form a structure called the 
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telomeric loop or T-loop. This structural formation further allow chromosomes to prevent loss 
of genetic material and offer protection against DNA damage (Greider, 1999) 
1.4.1.2. Telomeres and the “end-replication problem” 
In addition to being ends of linear chromosomes, telomeres are not properly replicated during 
lagging-strand synthesis and thus shorten with every cycle of cell division, a phenomenon called 
“end replication problem” (Allsopp et al., 1992) (Fig. 7). During DNA replication, the DNA 
polymerase synthesises new DNA strand in the 5’ to 3’ direction. Due to its specificity, the DNA 
polymerase can successfully replicate the leading strand.  
 
Figure 7: Diagram showing synthesis of DNA in both the leading and lagging strand. The lagging strand 
requires presence of Okazaki fragments and results in an incomplete 5’ end. This mechanism is termed 
the “end-replication problem”. http://www.mun.ca/biology/desmid/brian/BIOL2060/BIOL2060-
19/CB19.html. 
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However, in the lagging strand, synthesis requires small DNA pieces called Okazaki fragments to 
initiate synthesis. These fragments work in conjunction with RNA primers. At the end of DNA 
synthesis, the last primer is removed leading to daughter molecules with a 5’ terminal gap, this 
was termed the “end-replication problem” (Lingner et al., 1997; Watson, 1972). 
Loss of these telomeric repeats would eventually prompt cells to exit the cell cycle, and enter 
replicative senescence; a state of permanent cell cycle arrest and a barrier to unlimited 
proliferation (Hayflick, 1965; Shay and Wright, 2005). Like senescent cells, differentiated cells 
have stopped dividing and thus reached their final non-replicative cell type. In some cases, cells 
bypass senescence and re-enter the cell cycle (Shankland and Wolf, 2000). This is often through 
the activity of the telomerase.  
1.4.2. The telomerase enzyme 
Telomerase is a holoenzyme and a multisubunit ribonucleoprotein (RNP) that consists of two 
essential components; the human telomere reverse transcriptase (hTERT) and the human 
telomerase RNA complement (hTERC) (Fig. 8) in addition to telomerase-associated proteins 
(Harrington et al., 1997). Telomerase maintains telomeres by synthesising telomeric repeats in 
a 5’ to 3’ fashion towards the distal end of the chromosome, thereby lengthening it (Blackburn, 
2005; Blasco et al., 1999).  
Telomerase is expressed in highly proliferating tissues such as germline cells, some stem cells 
and 85 - 90% of human tumour cells (Blasco et al., 1999; Kim et al., 1994). In contrast, 
telomerase activity is absent or expressed at very low levels in most adult somatic cells (Wright 
and Shay, 1992). The consequence of limited telomerase activity is progressive telomere 
shortening and restricted ability to allow cell division (Harley et al., 1990).  Progressive telomere 
shortening eventually trigger cells to exit the cell cycle and enter replicative senescence or 
apoptosis (Blackburn, 2000; Blasco et al., 1999; Bryan et al., 1997). However, telomerase 
reactivation has been identified as one of the processes that permits cells to escape 
senescence. In fact, ectopic expression of TERT in somatic cells is sufficient to promote 
unlimited cell proliferation (Bodnar et al., 1998; Davis et al., 2003). Moreover, this reactivation 
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is associated with cellular immortality which is observed in 85% of cancers (Shay and Bacchetti, 
1997). Furthermore, transfection of retinal pigment epithelial cells and foreskin fibroblasts with 
an expression vector containing the TERT gene resulted in substantial increase in telomere 
length and extended cell life span (Bodnar et al., 1998). This makes telomerase a perfect 
candidate for studies concerning cell cycle events that prevent cell cycle exit such as 
senescence or differentiation (Shankland and Wolf, 2000). 
 
 
Figure 8: The process of telomere repeats addition by the telomerase enzyme (hTERT using hTERC as a 
template (Shay and Wright, 2006). Image reproduced with permission from the Nature Publishing 
Group. 
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1.4.2.1. The human telomerase RNA component (hTERC) 
The human telomerase RNA component (hTERC) consists of an RNA sequence that is 
complementary to the telomeric DNA. This RNA sequence serves as a template for de novo 
addition of deoxynucleotides to the G-rich telomere strand by the major catalytic subunit of the 
telomerase enzyme; hTERT (Feng et al., 1995; Guilleret et al., 2002).  
1.4.2.2. The human telomerase reverse transcriptase component (hTERT) 
The hTERT utilises the hTERC as a template for telomere synthesis (Lingner et al., 1997). Unlike 
the hTERC which is present in all cell types, the hTERT mRNA is only detected in telomerase 
positive cells and therefore recognised as the rate limiting determinant of telomerase 
enzymatic activity (Counter et al., 1998; Kim et al., 1994). Indeed several studies have 
investigated the role of the hTERT component as the key regulator of telomerase activity. 
Nakayama and colleagues (1998) introduced the wild-type hTERT gene into normal 
differentiated fibroblast cells and observed a significant increase in telomerase activity 
(Nakayama et al., 1998).  
The hTERT component is mainly known for its specialized role in telomere maintenance. The 
hTERT is primarily located in the nucleus where it elongates or stabilises telomeres. Reports 
have shown that it also localizes to mitochondria (Gordon and Santos, 2010) and the cell 
surface of HEK293 and MDA-MB321 cells (Naidoo et al., 2015). The function of hTERT in the cell 
surface and mitochondria is largely unknown.  The available findings point to a non-telomere 
related role that encourages cell proliferation through interaction with various proteins 
including the 37kDa/67kDa laminin receptor (LRP/LR) (Naidoo et al., 2015).  Several other 
studies have revealed other noncanonical functions of hTERT that influence cancer growth and 
progression. Two signalling pathways involved in development, oncogenesis and inflammation 
have been shown to interact with hTERT to induce cellular proliferation. These are the nuclear 
factor kappa B (NF-ĸB) and the Wnt/β-catenin pathways.  
The transcription factor NF-ĸB is a crucial inflammation and development regulator (Biswas and 
Tergaonkar, 2007). Dysregulation of the NF-ĸB pathway has been associated with pathogenesis 
of various human diseases including inflammation and cancer (Akiyama et al., 2003). The NF-ĸB 
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transcription factor has been shown to interact with the TERT protein and regulate nuclear 
translocation of TERT in myeloma cells (Akiyama et al., 2003).  Furthermore, studies have 
shown that upregulation of hTERT promotes activity of NF-ĸB and expression of NF-ĸB related 
genes (Ding et al., 2013; Ghosh et al., 2012). These findings suggest that hTERT may be a 
transcriptional regulator of the NF-ĸB pathway.  
The hTERT has also been reported to regulate the Wnt/β-catenin pathway. This particular 
pathway is mainly involved in embryogenesis and regulation of cell polarity and potency 
(Clevers and Nusse, 2012). Alteration of the Wnt/β-catenin signalling has been implicated in 
susceptibility to cancer and developmental disorders (Clevers and Nusse, 2012; Martinez and 
Blasco, 2011). This was first observed in hair follicles of transgenic mice engineered to 
conditionally express inactive TERT. The induced TERT expression resulted in activation of hair 
follicle stem cells and ultimately triggering hair growth independently of the TERT catalytic 
function (Choi et al., 2008). Further analysis revealed that TERT upregulation induced 
expression of development-related genes closely controlled in the Wnt/β-catenin pathway 
(Choi et al., 2008).  
Another study by Park and colleagues (2009) revealed that introduction of TERT in Xenopus 
embryos and mice embryonic stem cells promoted over-proliferation of cells (Park et al., 2009). 
In addition, TERT was also shown to interact with transcription factor Brahma-related gene 1 
(Brg1); a role player in the Wnt/β-catenin pathway shown to maintain tumour initiation cell 
phenotype in cancers (Park et al., 2009). The Wnt/β-catenin pathway dysregulation via TERT 
expression has also been suggested to induce proliferation of renal epithelial cells in transgenic 
mice (Section 1.3.2.4.) (Shkreli et al., 2012). In contrast, defects associated with dysregulation of 
the Wnt/β-catenin pathways were absent in TERT deficient study organisms and cell lines (Choi 
et al., 2008; Clevers and Nusse, 2012; Martinez and Blasco, 2011; Park et al., 2009; Shkreli et al., 
2012). These findings revealed that stimulation of NF-ĸB and Wnt/β-catenin pathways by TERT 
and vice versa may be the underlying mechanism that drives expression of genes involved in 
tumour survival and proliferation (Li and Tergaonkar, 2014).  
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1.5. Genome-wide Association Studies (GWAS) on telomere-associated 
genes  
GWA studies were introduced in the late 1990s. At that time, most of the genetic studies used 
linkage analysis to detect susceptibility loci in complex diseases. Findings from linkage studies 
indicated that predisposition factors to majority of complex diseases are either relatively weak, 
highly heterogeneous or both. Due to the low success rates of linkage analysis, more statistical 
power was required to reliably determine these susceptibility factors. Researchers 
demonstrated that rather than studying affected individuals only, association studies provided 
a more reliable statistical power to detect weak effects by comparing affected and non-affected 
individuals. This would identify loci or alleles that were more prevalent in either group (Risch 
and Merikangas, 1996).  
There is increasing evidence on the role of telomere dynamics in disease susceptibility as well 
as driving disease progression. To understand the variation of telomere biology genes and the 
implication in disease, several GWA studies have been performed. These studies set out to 
identify disease susceptibility factors in genes and pathways associated with telomeres. Several 
studies have been performed to date to assess the common variants in telomere related genes 
and their association with disease. It is noteworthy that most of these studies were only 
performed in non-African populations. Numerous variants have been identified within the 
hTERT gene and have been associated with cancers and ageing disorders. These include 
gliomas, lung and breast cancers as well as idiopathic pulmonary fibrosis (Mirabello et al., 2010; 
Pooley et al., 2010; Qu et al., 2014). For example, the variant or single nucleotide polymorphism 
(SNP) with reference SNP number rs2736100 located on chromosome 5: 1 284 601 (5: g. 
1284601(A>C)). This SNP is found in intron 2 of the hTERT gene and has been suggested to alter 
hTERT expression and influence telomere length (Codd et al., 2013). This particular SNP results 
in an Adenine to Cytosine (A>C) nucleotide change. The rs2736100 has been reported to be 
associated with increased risk of developing several diseases including gliomas (Liu et al., 2010; 
Shete et al., 2009; Wrensch et al., 2009), lung and breast cancers (McKay et al., 2008; Shen et 
al., 2010; Truong et al., 2010; Wang et al., 2010) and interestingly, bladder cancers (Gago-
Dominguez et al., 2011).  
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Similarly variation within the telomere associated genes has been implicated in several 
diseases. For example some germline and somatic mutations in the dyskerin, hTERT and hTERC 
genes are associated with telomere shortening, susceptibility to cancer and premature ageing 
(Carroll and Ly, 2009). Figure 9 highlights some of the mutations within the hTERT gene that 
have been associated with diseases such as acute myeloid leukemia (AML). 
 
 
 
Figure 9: Different single nucleotide polymorphisms (SNPs) within the hTERT gene with clinical 
implications that confer susceptibility to certain cancers (Carroll and Ly, 2009). The SNPs outlined in the 
image are non-synonymous i.e. result in amino acid change. These SNPs confer susceptibility to several 
of the cancers and ageing disorders outlined. 
Interestingly, GWA studies revealed somatic mutations that could also drive disease 
progression or increase disease risk. Importantly, more studies were channelled towards 
identifying these susceptibility factors within the critical component of telomerase; the hTERT 
gene and comparing average telomere length in affected and unaffected individuals.  
1.5.1. Variation within the hTERT gene 
The gene that codes for the catalytic reverse transcriptase subunit of the telomerase enzyme is 
located on chromosome 5p15.33 (Greider and Blackburn, 1985). The hTERT gene consists of 16 
exons and 15 introns (Cong et al., 1999). Mutations within the gene itself were shown to be 
associated with high telomerase activity in different cancers (Fig. 9).  
KEY  
AA: Aplastic Anaemia 
DC:  Dyskeratosis Congenita 
IPF: idiopathic pulmonary 
fibrosis 
AML: acute myeloid leukemia  
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Several research groups have described associations between the rs2736100 variants and 
cancer risk, however most results were inconclusive of the allele conferring risk (Gago-
Dominguez et al., 2011; Jin et al., 2009; Shen et al., 2010; Wang et al., 2010; Wrensch et al., 
2009). In addition the most of the associations were reported non-African populations in 
Europe and Asia. Although the variant has been associated with adenocarcinoma risk in African-
Americans (Spitz et al., 2013), a lack of association with breast cancer risk in women of African 
ancestry was reported (Zheng et al., 2012). This is the only study to date that has assessed the 
role of this particular gene in disease pathogenesis in African ancestry.  
Currently available allele and genotype frequencies accessed through 1000 Genomes and 
HapMap Data, revealed no significant difference in the distribution of the alleles across 
different populations. The African populations genotyped for the SNP were assessed to 
annotate the variant and determine the distribution in different populations. No association 
studies to date have been performed to investigate the role of this particular variant in disease 
susceptibility. Our bioinformatics analyses have shown that there is still missing data on the 
pathogenicity and distribution of some of the hTERT variants which are clinically important risk 
alleles in non-African populations.  
Another specific variant within hTERT is rs2736098, and has been previously shown to confer 
risk to lung cancer in Asian, African American and European populations, as well as bladder 
cancer in European populations. Even though the variant has been shown to have clinical 
importance in disease susceptibility, there is still limited data on the distribution of this 
rs2736098 in different populations. Most of the association studies were performed in Asian 
populations.  
Similarly, studies have shown that rs401681 is not associated with telomere shortening, breast 
cancer colorectal cancer, or melanoma in Caucasians (Pooley et al., 2010). Furthermore, 
another study revealed association with decreased risk of oesophageal cancer in Chinese 
individuals (Yin et al., 2014). In contrast, a meta-analysis revealed that the T allele is associated 
with increased risk for pancreatic cancer in Chinese individuals (Liu et al., 2014).  
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However, components that influence the expression of hTERT such as the promoter and 
minisatellite (MNS16A) have become interesting candidates to be tested for association with 
several diseases including cancer and ageing disorders (Blasco, 2005). Numerous SNPs have 
been identified and found to be associated with increased telomere stability and telomerase 
activity in different cancers (Petersen et al., 2010; Prescott et al., 2011; Terry et al., 2012; 
Varghese and Easton, 2010). 
1.5.1.1.1. The hTERT promoter 
The promoter region of the hTERT gene consists of 300 bases upstream of the translation start 
site. These regions possess specific sequences that allow binding of transcription factors to 
initiate transcriptional activity. These regions control expression of genes and mutations in 
these regions may lead to a decreased or increased expression of specific genes. Recently, 
several studies have identified hTERT promoter variants and their role in disease progression. 
the analysis of whole genome sequence data of malignant tumours revealed two common 
hTERT promoter variants in 89% of the tumours analysed. These variants are located on 
chromosome 5 at positions 1 295 228 C>T and 1 295 250 C>T; hereafter termed C228T and 
C250T, respectively (Huang et al., 2013). These variants within the hTERT promoter influence 
cancer susceptibility (Table 1). Furthermore, these variants in the hTERT promoter have been 
hypothesised to play a role in altering hTERT expression (Shkreli et al., 2012).  Another study 
verified the findings of Huang et al., 2013 and reported similar variants in different thyroid 
cancer types (Vinagre et al., 2013). Furthermore, promoter mutations were identified in 
bladder tumours and cell lines (Theodorescu and Cech, 2014).  
In addition, studies have shown that hTERT variants are useful markers for the severity of 
diseases such as cancer and ageing disorders (Calado et al., 2009; Kinnersley et al., 2012).  
Indeed a significant association of the variants with high levels of hTERT mRNA expression has 
been reported (Vinagre et al., 2013). Most of these studies were performed in non-African 
population (Bellido et al., 2013; Yan et al., 2014). Thus identifying variants within the genetically 
diverse African population that influence hTERT expression may lead to better understanding of 
disease. Evidence from mice models suggests that TERT upregulation may play a role in CKD 
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susceptibility. Therefore determining variants that alter hTERT expression could be used as 
valuable biomarkers for testing susceptibility to CKD. This may identify individuals at risk and 
lead to alternative treatment strategies. In addition, understanding the role of telomerase and 
telomeres in CKD may give information regarding mechanisms that lead to the cell-cycle re-
entry of differentiated podocytes. 
Table 1: Presence of the C228T and C250T hTERT promoter mutations in different human cancers. Table 
adapted from (Vinagre et al., 2013).  
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1.5.1.1.2. The hTERT minisatellite (MNS16A) 
In addition to gene promoters influencing expression of genes, minisatellites located upstream 
and/or downstream of genes play a crucial role as regulators of gene expression (Jeffreys et al., 
1985). Minisatellites are variable number tandem repeats (VNTRs) that have differing number 
of repeats among different individuals. This difference in the number of repeats influences the 
level of gene expression in certain genes (Jeffreys et al., 1985; Vergnaud and Denoeud, 2000). 
Within the hTERT gene, several minisatellites and microsatellites have been identified. One 
specific hTERT minisatellite located downstream of the hTERT gene is the MNS16A. This 
particular VNTR has been suggested to affect the activity of the hTERT promoter, thus altering 
hTERT expression in lung cancer (Wang et al., 2003). Figure 10 shows the position of the 
MNS16A in the hTERT gene. The MNS16A has been suggested to influence the expression of 
hTERT through regulation of the hTERT mRNA expression (Hofer et al., 2011; Wang et al., 2003; 
Wang et al., 2008). In fact Wang et al., 2003 reported that the antisense hTERT mRNA has a 
biological function, which may be exerted through interference with hTERT levels.  
 
Figure 10: The genomic structure of the hTERT gene showing the exon and satellite DNA positions in the 
gene. Minisatellite MNS16A indicated by the red box. Obtained from Wang et al., 2003.  
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The regulation of the hTERT promoter by minisatellite is dependent on the size of the 
minisatellite. Several sizes (243 bp, 274 bp, 302 bp, 333 bp and 364 bp) of the MNS16A 
classified as either long (L) or short (S) have been previously identified (Hofer et al., 2011; Wang 
et al., 2003; Wang et al., 2008). These sizes have been used as a gold standard for 
characterizing the MNS16A. Some scientists argue that the long allele (L) is associated with high 
levels of hTERT expression whereas others argue that the short allele (S) is the high risk allele 
(Hofer et al., 2011; Hofer et al., 2013; Jin et al., 2011; Wang et al., 2003). However most of the 
studies revealed the long allele (L) as the associated risk factor (Xia et al., 2013).   
These findings may be unique to different populations and/or tissues as most of these studies 
were replicated in different populations using different cancer types. No study as far as I know 
has assessed the role of the MNS16A in kidney diseases such as HIVAN which display over-
proliferation of the podocytes which may link hTERT involvement in progression and severity of 
disease. Long MNS16A tandem repeats are associated with low promoter activity, thus the 
antisense hTERT mRNA does not interfere with normal hTERT expression leading to high hTERT 
activity which is then associated with cancer and “cancer-like” diseases. 
Justification 
Many studies have been successful at identifying variants found within telomere genes 
especially hTERT (Mirabello et al., 2009; Mirabello et al., 2010; Pooley et al., 2010; Prescott et 
al., 2011; Xia et al., 2013). However, the majority of these studies involved Asian and Caucasian 
populations with limited data available for African populations. With advancing technology, the 
cost of genotyping or sequencing has decreased dramatically over the past decade. Following 
this change, an unexpected increase in the sequence data available was observed. This included 
an increase in the African populations genotyped in the 1000 genomes project 
(http://www.1000genomes.org/). Despite the dramatic change, data associating detected 
variants to disease susceptibility in African populations is still limited. Identification of variation 
in telomere biology genes in Africans is crucial in understanding disease susceptibility and 
possible future medical intervention.  The findings of this project will hopefully improve our 
understanding of the molecular pathogenesis of CKD and the role of telomere biology in disease 
 
 
32 
 
susceptibility. This will ultimately contribute to the body of knowledge in CKD improving renal 
health outcomes and offering new insight in the study of drug design for CKD treatment. The 
following aims and objectives were investigated. 
1.6. Aims and Objectives 
1.6.1. Aims 
 To determine variation in the hTERT gene and promoter in different non-African 
populations and compare this to African populations. 
 To determine whether telomere genetics play a role in chronic kidney disease 
progression and severity regardless of HIV status. 
 
1.6.2. Objectives  
 Identify common genetic variants within the hTERT gene and hTERT promoter in African 
and non-African populations. 
 To optimise methodology using nucleic acids and protein extracted from HEK293 cell 
line. 
 Determine chronic kidney disease progression and severity using patient clinical 
information. 
 Identify South-African specific variants within the hTERT promoter. 
 Determine variation within MNS16A in study population. 
 Determine whether the hTERT promoter and MNS16A variants have an effect on hTERT 
expression and ultimately telomere length.  
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Chapter 2: Methods and Materials 
2.1. Materials 
2.1.1. Participant DNA  
DNA was obtained from kidney biopsies of 98 CKD participants with HIVAN, HIV positive with 
kidney disease (nonHIVAN) and HIV negative with kidney disease (HIVnegK). DNA from 61 
controls who are HIV positive without kidney disease (HIVPosNK) and HIV negative without 
kidney disease controls (CTRL) was provided. All individuals in the study identified themselves 
as black. The signed consent was obtained from control participants and patients that 
underwent kidney disease treatment at the Charlotte Maxeke Hospital, Johannesburg through 
a genetic study by Mr Alex Kasembeli. All patients were over the age of 18. Participants  were 
males and females. They are all deceased.  Ethical approval for this study was obtained from 
the Human Research Ethics Committee (Medical) of the University of the Witwatersrand with 
ethics clearance number M140346 (Appendix A). These DNA samples were assigned new 
identification names (Appendix C). 
2.1.2. Cell lines 
Mammalian cells were cultured and used to extract nucleic acids and cell lysate for downstream 
applications. Table 2 shows the cell lines and culture media/conditions used for each cell line. 
Table 2: Cell culture media used for the human embryonic kidney cell line (HEK293) in the study. 
Cell line Culture Media 
HEK293 
Human embryonic 
kidney cells 
89% Dulbecco's Modified Eagle's Medium (DMEM) (Hyclone) with 
4500mg/L glucose, sodium pyruvate and 4mM L-glutamine (Sigma), 
supplemented with 10% Foetal Bovine Serum (FBS; Hyclone) and 1% 
penicillin/streptomycin (Sigma). 
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All plastics used to culture cells were obtained through Sigma. The T25 and T75 cell culture 
flasks (Sigma) were used to plate and grow cells.   
2.2. Methods 
2.2.1. Cell Culture 
All cell culture work was performed in the ESCO Airstream Class II laminar flow hood (Life 
Technologies). Cell lines used in this research are listed in the left column in Table 2. These cell 
lines were incubated in a humid incubator with 5% CO2 at 37 °C (NÜVE CO2 incubator EC 160) 
and sub-cultured when confluent. Cells were regularly fed and re-seeded until confluent. The 
culture media components for the HEK293 cell line (Table 2)  
The cells were either harvested for down-stream applications, sub-cultured, transfected with 
siRNA or frozen for long term storage at -80 °C. The cells were washed with 1-2 ml 1X PBS 
(Sigma Aldrich) and treated with 1-2 ml of pre-warmed Trypsin (Sigma Aldrich) at 37 °C to 
detach the cells from the culture flasks prior to splitting and sub-culturing. The trypsin reaction 
was terminated by the addition of respective pre-warmed culture media (4 ml in T25 culture 
flasks and 8 ml in T75 culture flasks). The cells were then counted using a haemocytometer. 
Based on the number of cells counted, a certain amount of cells was resuspended in warm 
culture media and plated in either a T25 of T75 cell culture flasks.  
Successfully cultured cell lines (HEK293 and MDA-MB-231) were transfected with a universal 
negative control esiRNA RLUC (Sigma Aldrich). The purpose of this experiment was to learn the 
technique for future use.  Briefly this involved preparing a transfection media by mixing 5 µL of 
1000 ng/µL esiRNA with transfection media. One mL of the transfection media was added to 9 
mL of freshly prepared warm cell culture media (Table 2). This mixture was added to the flask 
with cells and incubated for 24 hours at 37 °C and 5% CO2 levels in a humid Nűve incubator. 
Following the 24 hours incubation, the media was discarded and fresh 10 mL media was added 
to the plate and incubated for a further 72 hours with constant media change.  
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To enable long-term storage, some of the cells were frozen in liquid nitrogen. Briefly this 
involved transferring 1 - 2 mL of cells resuspended in media into 2 mL cryovials. The cryovials 
were then inserted in a control rate freezer containing DMSO. This control rate freezer with 
vials containing cells was then stored at -20 °C overnight. After this, the control rate freezer 
(AEC-Amersham, United States) was then transferred to -80 °C fridge overnight. The vials were 
removed from the control rate freezer and transferred into a liquid nitrogen tank and left for 
long term storage. To thaw the cells, cell culture media was pre-warmed to 37 °C and cryovial 
removed from the liquid nitrogen. The cryovial containing cells were slowly defrosted at room 
temperature and 1 mL of cells added into the flask containing pre-warmed cell culture media. 
2.2.2. DNA Extraction and Quantification  
The DNA was extracted from the HEK293 cell line using the DNA Extraction Kit (Thermo 
Scientific) as the manufacturer’s instructions. Briefly, the procedure involved removing the cell 
culture media from the confluent cells and treating them with trypsin (Sigma) for 1 – 2 minutes 
at 37 °C until they detached. The reaction was stopped by addition of 9 ml of culture media 
(media prepared as described in table 2). The cell suspension was transferred to a 15 ml falcon 
tube (Becton Dickson) and centrifuged at 1 500 rpm for 10 minutes. The supernatant was 
removed and pellet resuspended in 5–10 ml of 1X PBS depending on the pellet size.  The 
suspension was transferred into six 1.5 ml Eppendorf tubes and centrifuged at 250 × g for 5 
minutes. The supernatant was removed and DNA was extracted from cell pellets using the 
GeneJET Genomic DNA purification Kit (Thermo Scientific) as per manufacturer’s instruction.  
Briefly, the cell pellet was resuspended in lysis buffer to lyse the cells. Proteinase K solution was 
then added to digest proteins. The mixture was then incubated at 56 °C for 10 minutes. 20 µL of 
RNAse A solution was added to the mixture and incubated at room temperature for 10 minutes 
to allow RNA degradation. 400 µL of 50% ethanol was added and mixed by vortexing.  The 
prepared lysate was then transferred into a spin column inserted in a collection tube. This was 
then centrifuged and subjected to two wash steps. In the final step, elution buffer containing 
Tris-EDTA was used to elute the extracted DNA. The DNA was then quantified using the 
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NanoDrop ND1000 system (Thermo Scientific) and stored at -20 °C for downstream 
applications.  
2.2.3. RNA Extraction and Quantification 
To extract RNA, the direct-zol RNA miniprep kit (Zymo Research) was used as per 
manufacturer’s instructions. This procedure briefly involved resuspending cell pellet in 1 mL 
TRI-reagent (Sigma) and 1 mL 100% ethanol. The mixture was then transferred into a spin 
column containing a collection tube and centrifuged for 30 seconds at 13 000 xg centrifugation 
speed. The column was subjected to two washing steps using buffers diluted in 100% ethanol. 
The RNA was then eluted using 50 µL of DNAse/RNAse free water. The sample was ran on a 1% 
agarose gel to confirm successful extraction. The remainder volume of RNA was stored at -80 °C 
for further use.  
2.3. Real-time PCR (qPCR) 
2.3.1. hTERT gene expression 
To optimise determination of hTERT gene expression, RNA extracted from HEK293 cell line was 
converted into cDNA using the Maxima cDNA synthesis kit (Thermo scientific) containing RNAse 
inhibitor and DNAse as the manufacturer’s instructions. This briefly involved mixing the 
template RNA with a 5X reaction mixture containing reaction buffer, dNTPs, oligo dT and 
random hexamer primers, as well as the maxima enzyme mix containing the reverse 
transcriptase and RNAse inhibitor. Nuclease free water was added to make a 20 µL reaction. 
This mixture was briefly centrifuged and subjected to the following cycling conditions in a 9600 
Thermocycler (BIORAD); incubation for 10 min at 25 °C followed by 15 min at 50 °C. To 
terminate the reaction, reaction mixture was incubated at 85 °C for 5 min. The samples were 
then stored at -20 °C for downstream applications.  
The converted cDNA was subjected to a probe based application for detection by real-time 
quantitative PCR (qPCR). This was used to determine hTERT expression in the HEK293 cell line 
relative to the internal reference gene; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
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(Schmittgen and Zakrajsek, 2000). GAPDH is used as a reference gene in many gene expression 
quantification studies (Suzuki et al., 2000). Reference genes are usually expressed in all cell 
types at a relatively constant expression level (Janssens et al., 2004).  
Quantitative PCR is performed using a thermal cycler which allows elucidation of each nucleic 
acid sample with a beam of light at a specified wavelength permitting the detection of 
fluorescence emitted by the excited fluorophore (Freeman et al., 1999). The first step of the 
technique employs the conventional PCR procedure. This requires that each nucleic acid sample 
is in equivalent amounts and that each sample under analysis amplifies with the same efficiency 
to allow quantitative analysis (Freeman et al., 1999). The amplified products are then 
illuminated and normalised to the amplification of a reference gene prior to analysis.   
2.3.2. Characterisation of the hTERT promoter and MNS16A 
2.3.2.1. DNA Amplification  
The University of California Santa Cruz (UCSC) genome browser accessed through the web 
address http://genome.ucsc.edu/ was used to determine the fragment sizes in base pairs (bp) 
of the expected sequence with nucleotides in the database that lie between and include the 
primer pair. The browser uses an application called In-silico PCR which searches a sequence 
database with a pair of PCR primers. When successful, the search returns a sequence output file 
containing all sequence in the database that lie between and include the primer pair as outlined 
in table 4. Primers used for this study were previously designed by authors cited in table 3. 
Table 3: List of previously designed hTERT promoter and MNS16A primers used in this study. 
Primer Name Sequences (5’-3’) Region Reference 
MNS16A_F AGGATTCTGATCTCTGAAGGGTG MNS16A satellite (Wang et al., 2003) 
MNS16A_R TCTGCCTGAGGAAGGACGTATG MNS16A satellite (Wang et al., 2003) 
Promoter_F CCAGGCCGGGCTCCCAGTGGAT hTERT promoter (Zhang et al., 2000) 
Promoter_R TCCTGCTGCGCACGTGGGAAGCC hTERT promoter (Zhang et al., 2000) 
 
 
 
38 
 
Table 4: The hTERT promoter fragment size and sequence obtained from the UCSC In-Silico PCR. The 
sequences of the pair of primers are underlined and bolded.  
Sequence size 
Expected Promoter Sequence 
CCAGGCCGGGCTCCCAGTGGATTCGCGGGCACAGACGCCCAGGACCGCGCTTCCCACGTGGCGG
AGGGACTGGGGACCCGGGCACCCGTCCTGCCCCTTCACCTTCCAGCTCCGCCTCCTCCGCGCGGAC
CCCGCCCCGTCCCGACCCCTCCCGGGTCCCCGGCCCAGCCCCCTCCGGGCCCTCCCAGCCCCTCCCC
TTCCTTTCCGCGGCCCCGCCCTCTCCTCGCGGCGCGAGTTTCAGGCAGCGCTGCGTCCTGCTGCGC
ACGTGGGAAGCC 
275 bp 
Expected Minisatellite Sequence  
AGGATTCTGATCTCTGAAGGGTGGGTAGGGTGGGGCAGTGGAGGGTGTGGACACAGG
AGGCTTCAGGGTGGGGCTGGTGATGCTCTCTCATCCTCTTATCATCTCCCAGTCTCATCTC
TCATCCTCTTATCATCTCCCAGTCTCATCTGTCTTCCTCTTATCTCCCAGTCTCATCTGTCATC
CTCTTACCATCTCCCAGTCTCATCTCTTATCCTCTTATCTCCTAGTCTCATCCAGACTTACCT
CCCAGGGCGGGTGCCAGGCTCGCAGTGGAGCTGGACATACGTCCTTCCTCAGGCAGA 
302 bp 
 
2.3.2.2. The hTERT minisatellite  
A gradient PCR was performed using 20 ng/µL DNA extracted from HEK293 cells and 
oligonucleotide primers previously (Wang et al., 2003). In the literature, different authors had 
used various annealing temperatures for the PCR amplification of the hTERT minisatellite 
(MNS16A). The recommended annealing temperatures were 60 °C, 61 °C and 65 °C. Thus to 
determine optimum annealing temperature the gradient was performed at 60-65 °C using Mini 
thermal cycler (BIORAD). To prepare the reaction, the Phusion Flash HiFi Master mix (Thermo 
Fisher Scientific) was prepared as the manufacturer’s instruction. The master mix contained all 
the necessary reaction components for PCR except for template DNA and primers. The MNS16A 
forward (F) and reverse (R) primers used for MNS16A PCR amplification are listed on Table 3. 
The cycling conditions briefly involved initial denaturation at 98 °C for 1s, 35 cycles of 98 °C for 
10s; 60 – 65 °C for 15s; 72 °C for 30s; and final extension at 72 °C for 1 minute.   After 
completion of PCR run, the PCR products were resolved in a 2.5% agarose gel prepared as 
outlined in Appendix B.   
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The DNA obtained from participants was amplified by PCR to characterise the hTERT 
minisatellite (MNS16A). Successive cycles of denaturation of target DNA, annealing of primers, 
and extension of primers from their 3’ ends by DNA polymerase, amplifies the region of 
interest. 10 µl PCR reactions were prepared and a no template control (NTC) was included to 
detect contamination (Appendix B). The reaction was carried out using the 9600 thermal cycler 
(BIORAD) and PCR products stored at – 20 °C until further use. 
The amplified fragments were then resolved by 1 % agarose (Conda, Low EEO) gel 
electrophoresis using 1X Tris-Borate EDTA (TBE) buffer to validate the PCR amplified the correct 
fragment size.  
2.3.2.3. Agarose Gel electrophoresis 
Gel electrophoresis is a type of technique used to separate DNA fragments by size in an electric 
field. The technique utilises crosslinks that are formed when the agarose powder is mixed with 
Tris-EDTA buffer. These crosslinks determine whether a nucleic acid fragment can pass through. 
The larger the fragment size the less mobile the fragment will be.  
The hTERT promoter and MNS16A amplified fragments were resolved in 1% and 2.2% agarose 
gel respectively in a 1X TBE buffer. The gel was left to run for 40 – 60 minutes at 80 volts and 
viewed using the gel doc imaging system (BIORAD). A 1Kb plus DNA ladder (GeneDirex) was 
used as a molecular marker to identify the size of fragments separated by gel electrophoresis.  
2.3.3. Sequencing and Sequence Analysis 
Prior to sequencing, samples (PCR products and gel slabs) were purified using PCR and Gel 
purification kits (Thermo Scientific) as the manufacturer’s instructions. After the correct size 
fragment has been validated, the fragment of interest was extracted from the gel and purified 
using the GeneJet Gel extraction kit (Thermo K0691). This briefly involved cutting out the band 
of interest from the agarose gel and weighing it on a weighing scale. After determination of the 
weight of the gel, a 1:1 (binding buffer: gel weight) ratio of binding buffer is added to the gel 
(i.e.  100 µl of binding buffer for every 100 mg of agarose gel). This was then incubated at 60 °C 
for ten minutes to allow the gel to dissolve. Twice the volume of 100% isopropanol was added 
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to the mixture and transferred to a column with a collection tube. After several centrifugation 
and wash steps, the DNA was eluted in 25 µL using the elution buffer (10 mM Tris-HCl, pH 8.5). 
Purified products were then validated by running 1 µl on a gel against a 1Kb ladder (Inqaba 
Biotech). The validated products were sequenced by Inqaba Biotec This procedure involves 
determining the order of the nucleotide bases in a DNA sequence. The type of sequencing used 
to carry out the reaction is the Sanger sequencing/Chain termination method which utilises 
dideoxynucleotides (ddNTPs) to terminate elongation of the sequence of interest (Sanger et al., 
1977).  
Sequence analysis was carried out using sequence alignment softwares such as Bioedit and/or 
Seqscanner. The softwares align and compare the sequence of interest with known human 
genome sequences in the National Centre for Biotechnology Information (NCBI) database 
GRCh37.p10 reference assembly (GCF_000001405.22). This allowed the detection of any 
variation within the hTERT promoter and minisatellite sequences in the study of black South 
African population.  
2.3.4. Determination of telomere length  
2.3.4.1. Telomere length determination by Single Telomere Length Analysis (STELA) 
Telomere length was determined using the modified Single Telomere Length Analysis (STELA) 
(Baird et al., 2003). The first step involved PCR amplification of the telomere repeats and 
regions of DNA adjacent to telomeres (Fig. 11). The DNA was first diluted to 10ng/μL using 10 
mM Tris_EDTA (TE) (Sigma). The diluted DNA was then diluted to 250 pg/μL containing 0.25 μM 
telorette 2 primer. This was prepared by mixing 1 µL of 10 ng/µL genomic DNA, 1 µL of 10 mM 
telorrette primer and 38 µL of 10 mM TE buffer (Sigma) and stored at - 20°C. To prepare the 
PCR reactions, 1X Phusion Flash High-Fidelity PCR master mix (Thermo Scientific) containing all 
the necessary reaction components for PCR (High fidelity Taq polymerase, dNTPs and buffers) 
was mixed with 0.5 µM of teltail primer with either 17pseq1rev or XpYpE primers outlined in 
Table 5.  The PCR cycling conditions were as follows; 98 °C for 10 seconds, 23 cycles of 98 °C for 
 
 
41 
 
2 seconds; 65 °C (XpYpE)/ 59 °C (17 pseq1rev) for 30 seconds, 72 °C for 5 minutes and final 
elongation step at 72 °C for 10 minutes. 
The amplified products were then resolved by submarine 0.5-0.8% agarose gel electrophoresis 
in Tris-Acetate EDTA (TAE) buffer for 18 hours. The separated fragments were transferred to a 
nylon membrane by alkaline Southern blotting (Koetsier et al., 1993). The DNA fragments were 
expected to maintain the separation pattern they had on the gel. It should be noted that the 
bands were not visible on the gel as expected. 
Table 5: List of primer sequences for STELA PCR reactions. 
Primer name Primer sequence Reference 
Telorrette 5'-TGCTCCGTG CATCTGGCATCTAACCCT-3'  (Baird et al., 2003) 
Teltail 5'-TGCTCCGTGCATCTGGCATC-3'  (Baird et al., 2003) 
17pseq1rev 5'-GAATCCACGGATTGCTTTGTGTAC-3'  (Britt-Compton et al., 2006) 
XpYpE 5'-TTGTCTCAGGGTCCTAGTG-3' (Britt-Compton et al., 2006) 
 
The transferred products were detected using the TeloTAGGG kit (Roche) as follows; the 
blotted DNA fragments were hybridised to a digoxigenin (DIG)-labelled probe specific for 
telomeric repeats. The membrane was then incubated with a DIG-specific antibody covalently 
connected to alkaline phosphate. Finally, the restrained telomere probe DIG was visualized by 
virtue of alkaline phosphatase metabolizing CDP-Star, a highly sensitive chemiluminescence 
substrate in a ChemiDoc (BioRad). The procedure was unsuccessful after several trials. 
Consequently the relative telomere length was assessed using real-time quantitative PCR as 
described in section 2.3.4.2. 
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Figure 11: The principle of telomere extension using the STELA technique. Showing the primers and 
linkers involved in telomere extension. Reproduced with permission from the Nature Publishing Group 
(Baird et al., 2003). 
2.3.4.2. Relative telomere length determination by quantitative real-time Polymerase 
Chain Reaction (qPCR) 
Relative telomere length of participants was analysed using a modified method of quantitative 
PCR (qPCR) (Cawthon, 2002). All PCRs were performed on the light cycler 480 real time PCR 
system (Roche Diagnostics). Subsequently analysis was performed using the LC480 software 
version 1.5 (Roche Life Sciences). The experiment was prepared in triplicates for each DNA 
sample. Conditions are described in Appendix B. Genomic DNA extracted from HEK293 cell line 
and participants tissue  was mixed with LC480 SYBR Green I Master (Roche diagnostics) 
containing all the necessary reaction components for PCR,  the acidic ribosomal 
phosphoprotein (36B4) reference gene was amplified with primers 36B4u, 
CAGCAAGTGGGAAGGTGTAATCC and 36B4d, CCCATTCTATCATCAACGGGTACAA and nuclease 
free water. In a separate PCR reaction, respective primers pairs (Telomere length primers tel 1, 
GGTTTTTGAGGGTGAGGGTGAGGGTGAGGGTGAGGGT; tel 2, 
TCCCGACTATCCCTATCCCTATCCCTATCCCTATCC-CTA were used to determine telomere length.  
The standard curve was generated using HEK293 extracted DNA. The relative telomere length 
was determined using the ratio between telomere length and 36B4 expression (Cawthon et al., 
2003).  
2.3.5. Bioinformatics  
2.3.5.1. Determination of global variation in the hTERT gene and promoter 
With the aid of the Sydney Brenner Institute of Molecular Biosciences (SBIMB) staff, SNPs 
within the hTERT gene and promoter were identified in different populations across the globe. 
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The data collection and analysis was done using the 1000 genomes and HapMap data accessed 
through www.1000genomes.org/ and hapmap.ncbi.nlm.nih.gov/ respectively. The distribution 
of the allele and genotype frequencies were assessed in European, Asian, African and mixed 
populations. These were then compared to the African populations genotyped in 1000 
genomes to evaluate the differences observed in each population. In addition to African 
populations, sequence data from the black Sowetans in South Africa (BSO) (May et al., 2013) 
was also analysed.  
2.3.5.2. DNA Amplification  
The University of California Santa Cruz (UCSC) genome browser accessed through the web 
address http://genome.ucsc.edu/ was used to determine the fragment sizes in base pairs (bp) 
of the expected sequence with nucleotides in the database that lie between and include the 
primer pair. The browser uses an application called In-silico PCR which searches a sequence 
database with a pair of PCR primers. When successful, the search returns a sequence output file 
containing all sequence in the database that lie between and include the primer pair. 
2.3.6. Statistical analyses 
The MNS16A genotype and allele frequencies were determined by direct counting and 
deviation from Hardy-Weinberg Equilibrium (HWE) was tested. HWE was tested to establish 
whether genotype and allele frequencies in different populations remained constant in every 
generation with limited evolutionary influence. In order to determine whether a statistically 
significant association exists between CKD and MNS16A variants, analysis of variance (ANOVA 
and T-tests) and odd ratio (OR) was used. This briefly tests for the probability of presence or 
absence of disease in individuals with either long or short alleles of the MNS16A. The same 
tests were used to determine association between hTERT gene and promoter SNPs identified 
through bioinformatics analyses as described in section 2.3.5.1. All tests were performed at 
95% confidence intervals (CI). To correlate MNS16A variants and clinical data to relative 
telomere length (RTL), Pearson Spearman’s correlation was measured. Statistical analyses with 
a p value less than or equal to 0.05 were considered as statistically significant. All statistical 
analyses were performed using the GraphPad Prism statistics software version 5.1. 
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Chapter 3: Results  
Section 1: Genetic variation within hTERT gene in African populations 
and non-African populations. 
3.1. Chapter introduction 
The primary aim of this study was to determine whether telomere genetics play a role in kidney 
disease progression and severity in the presence or absence of HIV infection. The hTERT gene 
has been identified as a genetic risk factor in several diseases. It has been shown that 
upregulation of hTERT at any point of the cell cycle, proliferation is induced. More evidence is 
suggestive of a non-telomere related function of hTERT that promotes cellular viability, 
proliferation and inflammation. Even more so, regulatory regions such as the hTERT promoter 
and MNS16A have become important role players as they have been shown to influence hTERT 
gene expression and ultimately telomere length (Huang et al., 2013; Wang et al., 2014; Wang et 
al., 2003).  
It was predicted that participants who are HIV positive with kidney disease will present with 
variation in telomere length and telomere-related genes such as the hTERT. To test these 
predictions, the hTERT promoter was screened for mutations and MNS16A size was 
determined. The average telomere length was also measured.   One of the aims of the study 
was to determine genetic variation within the hTERT gene in African population and to identify 
any unique single nucleotide polymorphisms in these populations.  
3.2. hTERT gene  and promoter (Bioinformatics) 
To identify common genetic variants within the hTERT gene and promoter, data from genome-
wide association studies was obtained with the assistance of the Wits bioinformatics/Sydney 
Brenner Institute for Molecular Biology (SBIMB). The obtained data was compared to other 
populations genotyped and reported in the literature. These were subsequently analysed using 
GraphPad prism to test for statistical significance and other bioinformatics tools including 
HapMap, 1000 genomes and Ensembl. 
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3.2.1. The hTERT gene 
The hTERT gene located in chromosome 5p15.33 was assessed to identify variants in different 
populations. There was no significant differences in the distribution of the hTERT gene variants 
between African and non-African populations. Table 6 below shows all the different 
populations analysed in this study. This included all the populations genotyped through 
HapMap and 1000 Genomes. Included in the analysis as well is a black South African population 
(n = 94) from Soweto (BSO) genotyped in the birth to twenty (B2T) longitudinal cohort (Richter 
et al., 2007). The BSO population consisted of 94 unrelated Southeastern Bantu-speakers 
residing in the Soweto-Johannesburg area in South Africa. These individuals are all of self-
identify as of black ethnicity. The individuals were existing participants from a longitudinal 
study called the Birth to Twenty (B2T) cohort (Richter et al., 2007). This population is 
highlighted in bold in Table 6.  
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Table 6:  Populations analysed for variation in common hTERT gene and promoter variants. 
Population Code Population Description Super Population  
CHB Han Chinese in Bejing, China East Asian (EAS) 
JPT Japanese in Tokyo, Japan EAS 
CHS Southern Han Chinese EAS 
CDX Chinese Dai in Xishuangbanna, China EAS 
KHV Kinh in Ho Chi Minh City, Vietnam EAS 
CEU Utah Residents (CEPH) with Northern and 
Western European Ancestry 
European (EUR) 
TSI Toscani in Italia EUR 
FIN Finnish in Finland EUR 
GBR British in England and Scotland EUR 
IBS Iberian Population in Spain EUR 
YRI Yoruba in Ibadan, Nigeria African (AFR) 
LWK Luhya in Webuye, Kenya AFR 
GWD Gambian in Western Divisions in the 
Gambia 
AFR 
MSL Mende in Sierra Leone AFR 
ESN Esan in Nigeria AFR 
ASW Americans of African Ancestry in SW USA AFR 
ACB African Caribbeans in Barbados AFR 
BSO Black Sowetans in South Africa AFR 
MXL Mexican Ancestry from Los Angeles USA Admix American 
(AMR) 
PUR Puerto Ricans from Puerto Rico AMR 
CLM Colombians from Medellin, Colombia AMR 
PEL Peruvians from Lima, Peru AMR 
GIH Gujarati Indian from Houston, Texas South Asian (SAS) 
PJL Punjabi from Lahore, Pakistan SAS 
BEB Bengali from Bangladesh SAS 
STU Sri Lankan Tamil from the UK SAS 
ITU Indian Telugu from the UK SAS 
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There was no significant difference in the distribution of most hTERT common variants among 
the different populations (all variants outlined in appendix D). Even more so, there is still 
missing data on distribution of some of the common variants especially among African 
populations. The majority of the variants reported previously in 1000 genomes and HapMap are 
not associated with phenotype as main aim of these two projects was to only detect variants 
present in different populations. Most research was carried out predominantly in non-African 
populations where some of these variants are shown to be significantly associated with disease 
susceptibility. As a result of African countries mainly focusing their research on infectious 
diseases, data is very limited on the distribution and pathogenicity of many of the hTERT 
variants. For the purpose of this result, three variants within the hTERT gene shown to play 
significant roles in disease susceptibility were analysed.  
3.2.1.1. The rs2736100 
The variant rs2736100 (A>C) is located in intron 2 of the hTERT gene and is suggested to 
influence hTERT expression and telomere length (Codd et al., 2013). This particular variant has 
been associated with several diseases including lung and bladder cancers (Gago-Dominguez et 
al., 2011; McKay et al., 2008). No significant difference in allele distribution among the different 
populations was observed. It should be noted that individuals in the South Asian populations 
had slightly higher frequencies of the minor allele C compared to all the other populations 
represented in this analysis (Fig. 12) represented in blue. 
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Figure 12: Allele frequencies of the rs2736100 SNP in different populations. The South Asian populations 
presented with higher frequencies of minor allele C indicated in blue and boxed in black rectangle.   
 
3.2.1.2. The rs2736098 
Another variant of importance located in the second exon of the hTERT gene is rs2736098. This 
variant results in a synonymous substitution (A305A) of cytosine to thymine (C>T) at position 
1 293 971 on chromosome 5. Although synonymous variants do not alter the amino acid 
produced, the change in codon may influence the translational and protein folding kinetics. This 
change may result in a notable functional impact of the hTERT. All the African populations 
presented with very low frequencies of the minor allele T (10% or less) (Fig. 13). Interestingly, 
South Asian populations displayed significantly higher frequencies of the minor allele. These are 
highlighted in rectangular blocks (Fig. 13). 
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Figure 13: Allele frequencies of the rs2736098 SNP in different populations. The minor allele T is 
overrepresented in the South Asian populations. 
3.2.1.3. The rs401681 
Another variant of importance located in the hTERT gene is rs401681. This variant results in a 
cytosine to thymine (C>T). This particular variant has not been associated with risk to several 
diseases. In fact, the rs401681 is not associated with telomere shortening, breast and colorectal 
cancers, as well as melanoma in Caucasians (Pooley et al., 2010). The minor allele T is 
overrepresented in African populations (Fig. 14). Whereas in South Asian populations; the T- 
allele is in low frequencies. Highlighted in rectangular blocks (Fig. 14). 
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Figure 14: Allele frequencies of the rs401681 in different populations. 
3.2.1.4. The Southeastern Bantu speakers  
The three selected variants were also analysed in individuals genotyped in the Birth to Twenty 
(B2T) cohort (May et al., 2013). These included 94 unrelated Bantu speakers residing in the 
Soweto region of Johannesburg, South Africa. Allele frequencies were calculated to identify 
populations closely related to the Southeastern Bantu speakers (Table 7). 
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Table 7:  Distribution of rs2736100, rs2736098 and rs401681 alleles in the Birth to Twenty cohort. The 
populations in bold had allele frequencies very similar to the black South African population (BSO). 
Black Sowetans in South Africa (BSO) (n = 94) 
 Ancestral allele frequency Minor allele frequency Populations closely 
related to: 
rs2736100 A C ACB and LWK 
 52% 48% 
rs2736098 C T ACB, ESN, LWK and YRI 
94% 6% 
rs401681 C T ACB, ESN, MAG and YRI 
38% 62% 
 
Analysis of the three SNPs in the South African population revealed similar allele distribution to 
three populations i.e. ACB, LWK and YRI. Comparison of the black South African population at a 
global scale has always clustered with the LWK and YRI populations. Interestingly analysis of 
these three SNPs within the hTERT gene suggests that  BSO is similar to the ACB population. 
3.2.2. The hTERT promoter (Bioinfomatics) 
Bioinformatics data analyses of the common variants revealed no significant difference in the 
distribution of hTERT promoter SNPs in different populations (Table 8). Furthermore, the data 
obtained on these variants was strictly based on elucidating distribution of the variants among 
populations in different parts of the world (HapMap and 1000 Genomes). As a result, a 
phenotypic consequence of these variants is limited particularly in African populations. 
Interestingly, a significant difference (Fig. 15) in distribution of one particular variant rs2853669 
between African and non-African populations genotyped in the HapMap Project was observed. 
This particular variant results in a cytosine to thymine (C>T) change in 5: g.1295349(C>T) 
(GRCh37) and 5: g.1295234(C>T) (GRCh38). The rs2853669 has been associated with breast and 
oesophageal cancers in Caucasian and Asian populations but has not been associated with any 
disease susceptibility in Africans (Labussiere et al., 2014). 
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None of the common promoter variants were detected in the BSO population. The observed 
differences in distribution of rs2853669 variant in different populations warrants further 
research. This will increase the limited data on genetic variation in telomere-related genes and 
their potential role in disease susceptibility in Africans. 
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Table 8: Data showing different variants identified within the hTERT promoter in different populations and their genotype distributions. Variant 
rs2853669 (Chr5: 1295349) highlighted in red had the major differences between African and non-African populations. Only the two variant 
positions have been allocated rs numbers i.e. Chr5:1295349 (rs2853669) and Chr5:1295373 (rs35226131). 
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Figure 15: The hTERT promoter SNP rs2853669 genotype frequencies in different populations. 
Significant difference in distribution of genotypes between the different populations (*** = p<0.0001). 
CEU: Utah Residents with Northern and Western European Ancestry; CHB:  Han Chinese in Bejing, China; 
ESN: Esan in Nigeria; GWD: Gambian in Western Divisions in the Gambia; LWK: Luhya in Webuye, Kenya 
and MSL: Mende in Sierra Leone.  
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Section 2: The hTERT promoter and minisatellite (MNS16A) characterisation 
in study population.   
3.3. Study population 
DNA extracted from kidney biopsies of CKD participants and blood leucocytes of participants 
with no sign of CKD. Characteristics of the study participants are summarized in table 9. A total 
of 159 participants recruited from Charlotte Maxeke Hospital, Johannesburg: 98 patients with 
CKD (36 HIVAN; 32 HIV positive with CKD that is not HIVAN and 30 HIV negative with CKD) and 
61 controls (31 HIV positive and 30 HIV negative with no clinical evidence of CKD). 62% (98/159) 
of the participants had kidney disease and of the 98, 69% (68/98) were HIV positive. The study 
also consisted of 58.5% (93/159) females and 41.5% (66/159) males. The female participants 
were over represented in the HIVAN and nonHIVAN histopathologic groups. There was no 
significant difference (p>0.05) in the mean age within all histopathologic groups.  
Table 9: Clinical characteristics of study participants.  
  CKD Controls P value  
Histopathologic Groups 
Characteristic HIVAN     
(n=36) 
nonHIVAN 
(n=32) 
HIVnegK    
(n=30) 
HIVposNK 
(n=31) 
Controls 
(n=30) 
 
Men (%) 14(39%) 14 (44%) 18 (60%) 8 (26%) 12 (40%) ns 
Women (%) 22 (61%) 18 (56%) 12 (40%) 23 (74%) 18 (60%) ns 
Mean age (SD) 33.78 
(8.563) 
34.91 
(9.848) 
37.07 
(11.31) 
37.61 
(8.049) 
35.53 
(11.68) 
ns 
Mean Serum 
creatinine (µmol/L)  
577 285.1 337 108.5 - *** 
Mean eGFR (ml/min) 15.31 38.59 98.5 181.2 - * 
Mean Urea (mmol/L) 16.92 15.18 19.9 - - ns 
SD = standard deviation. 
eGFR = estimated glomerular flitration rate. 
ns = not significant at 95% confidence interval (p > 0.05). 
Statistically significant when *** (p ≤ 0.001) ** (0.001 < p ≤ 0.01) * (0.05 ≤ p < 0.01) 
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The mean age difference between all histopathological groups did not have a significant 
standard deviation (SD) ranging from 8.049 – 11.68). It is one of the recommendations that 
case-control studies involving telomere length measurement should consider age-matched 
participants as it is well know that progressive telomere shortening is a function of biological 
ageing (Blackburn, 2005b; Blackburn and Gall, 1978; Blasco et al., 1999; Greider and Blackburn, 
1985; Harley et al., 1990; Shkreli et al., 2012).  As result telomere length versus age analysis was 
performed.  
Serum creatinine and urea levels are utilized in pathology as measures of kidney malfunction. 
Creatine and urea are usually excreted from the body through the kidneys. High levels of these 
two molecules in the blood indicate progressive kidney failure (Naicker, 2002; Wyatt, 2012; 
Wyatt et al., 2007). Using creatinine levels, age, gender and ethnicity; estimated glomerular 
filtration rate (eGFR) was calculated. The lower the levels of eGFR, the higher the risk of CKD 
developing into end-stage renal disease (ESRD), a major cause of death. Individuals presenting 
with eGFR between < 15 to 40 ml/min are usually at stages 3 – 5 of CKD where they suffer from 
moderate to severe loss of kidney function. This was mostly observed in the participants with 
CKD who are also infected with HIV.   
Data regarding serum creatinine and urea levels in the control group was unavailable. This was 
because when control group participants were recruited, they were HIV negative and had no 
sign or symptom of CKD. Furthermore, urea levels were too low or undetectable in HIV 
seropositive group without CKD (HIVposNK). All clinical data is outlined in Appendix C. 
 
3.4. The hTERT promoter 
After completion of the gradient PCR procedure, the optimal annealing temperature for hTERT 
promoter amplification was determined. Using primers outline in the methods section 2.3.2.2. 
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Figure 16: Gel image showing hTERT promoter amplification using gradient PCR. Lanes 1 – 7 represent 
HEK293 extracted DNA of 20ng/µl concentration. Lane 7 shows the desired amplicon size (approximately 
275 bp) with limited smearing and non-specific amplification.  
The annealing temperature for lane 7 was 67.1 °C and this was selected for amplification of 
hTERT promoter in participant.DNA. 
3.5. The hTERT minisatellite (MNS16A) 
The hTERT minisatellite (MNS16A) was amplified using DNA extracted from HEK293 cell line. 
The primers MNS16A_F and MNS16A_R (Table 3) and conditions are outlined in the methods 
section 2.3.2.2. The gradient PCR resulted in an amplification of a 243 bp MNS16A.  
 
Figure 17: Gel image of a 2.5% agarose gel showing successful hTERT MNS16A amplification at eight 
gradient temperatures between 60°C and 65°C. Estimated size from UCSC Genome browser was 302 bp. 
Lane 8 was skipped due to suspicion of lane 8 product overflowing to lane 9. The temperature of 60 °C 
(lane 9) was selected for downstream PCR amplification of the MNS16A. 
300 bp 
200 bp 
100 bp 
 M  1  2  3   4   5   6   7    8    9  
NC 
M         1         2        3        4        5        6       7 
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After all of these adjustments, another gradient PCR of temperatures 60-65 °C was performed 
and was successful at all temperatures. The PCR products were run on a 2.5 % agarose gel (Fig. 
17). The 60–65 °C annealing temperatures showed successful amplification. However, a 
temperature of 60 °C was selected as the best annealing temperature for downstream analysis.  
3.6. Promoter (Participant DNA)  
To identify South African-specific variants in the hTERT promoter, the promoter region of 
approximately ~275 bp was amplified. The successfully amplified products were resolved on a 
1% agarose gel in 1x TAE buffer (Fig. 18).   
 
Figure 18: Gel image showing successful promoter amplification of participant DNA resolved in a 1% 
agarose gel. Lanes 1 – 5 shows successful amplification of the hTERT promoter ~275 bp. Lane N shows 
the negative control.  
 
These were then purified and sent for direct sequencing at Inqaba Biotech.  Figure 3 below 
shows alignment of sequencing results with the reference genome hg19, GRCh37. None of the 
reported promoter variants were detected in the study participant groups (Fig. 19). Neither did 
any new SNPs or SA-specific SNPS were identified. 
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Figure 19: Sequence alignment of the promoter region. Highlighted with boxes are the common promoter variant positions. None of the 
common promoter variants were detected in the study population. 
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3.7. MNS16A genotyping 
Genotyping for MNS16A allele sizes was successful in 150 study participants. In 9 participants 
amplification of the MNS16A was unsuccessful . However for these samples the promoter was 
successfully amplified. Since DNA amplification was successful at other loci, we ruled out DNA 
quality as the potential contributing factor. This observation suggests a possible deletion within 
the primer binding sites of the MNS16A region. The amplified products were successfully 
separated using agarose gel electrophoresis (Fig 20-21). In total, three different MNS16A 
genotypes were observed and classified as either long (302 bp) or short (243 bp and 274 bp).  
Amplified products were verified by direct sequencing. 
 
Figure 20: Agarose gel showing genotype patterns of the MNS16A in different individuals after PCR 
amplification. This shows the 302 bp and 243 bp MNS16A variants. Lane 1 = S/S (243/243 bp); Lane 2 = 
L/S (302/274 bp); Lane 3 = L/L (302/302 bp); Lanes 4-5 = S/S (274/274 bp); Lanes 6-11 = L/L (302/302 bp) 
and N = No template control.  
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Figure 21: Agarose gel showing genotype patterns of the MNS16A in different individuals after PCR 
amplification. This shows the 302 bp and 243 bp MNS16A variants. Lanes 1 to 9 showing individuals with 
the heterozygous genotype L/S (302 bp/243 bp). Lanes 10 -11 showing homozygous genotype S/S 
(243bp/243 bp). The M and N lanes represent the molecular weight marker and negative control (N) 
respectively.  
3.7.1. MNS16A genotype and allele frequencies 
The MNS16A genotype and allele frequencies were determined in the CKD and control groups 
(Table 10). It was noted that the participants with CKD had an over representation of the long 
MNS16A variant. In contrast, the long MNS16A variant was underrepresented in the no CKD 
groups regardless of HIV status (Fig. 22). It is noteworthy that the participants with suspected 
deletion within the MNS16A were all HIV positive. 
Table 10: The MNS16A genotype and allele distributions in study participants. 
  
  
 Genotypes   Alleles 
Groups Total (n) L/L L/S* S*/S* Deletion L S* 
HIVAN 36 22 (61%) 4 (11%) 4 (11%) 6 (17%) 48 (80%) 12 (20%) 
nonHIVAN 32 21 (66%) 4 (12%) 3 (9%) 4 (12%) 46 (76%) 16 (24%) 
HIVnegK 30 13 (43%) 12 (40%) 5 (17%) 0 38 (63%) 22 (37%) 
HIVposNK 31 1 (3%) 8 (26%) 21 (68%) 1 (3%) 10 (17%) 50 (83%) 
Controls 30 1 (3%) 3 (10%) 26 (87%) 0 5 (8%) 55 (92%) 
* represents either 243/272 bp short MNS16A sizes. 
Deletion: Samples that did not amplify the minisatellite but were successful for promoter 
amplification and thus suggestive of a possible deletion within the MNS16A primer binding 
sites. 
M       N          1         2        3        4         5         6        7          8        9       10     11 
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Figure 22: Distribution of MNS16A genotypes alleles between kidney disease and no kidney disease 
groups. There was a significant difference in the distribution of alleles between the two groups (*** 
p<0.0001). Analysis performed using the GraphPad Prism version 5.  
*** 
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Table 11: The difference in distribution of MNS16A genotypes and alleles with calculated odds ratio (OR) at 95% confidence interval (CI). 
Comparison 1 and 2 highlight the differences in distribution of MNS16A genotypes and alleles in different groups respectively. 
  
 Groups 
Comparison 1  Comparison  2 
Genotypes (L/L vs L/S* vs S*/S*) Alleles (L vs S*) 
HIVAN vs nonHIVAN OR = 0.7857 (0.1567 - 3.9386) p = 0.7693 OR = 1.3913 (0.5942 - 3.256) p = 0.4468 
HIVAN vs HIVnegK OR = 2.1154 (0.4802 - 9.3193) p = 0.322 OR = 2.3158 (1.10178 - 5.2692) p = 0.00453c 
HIVAN vs HIVposNK OR = 115.5 (11.915 - 1119.6) p < 0.0001a OR = 20 (7.907 - 50.5882) p < 0.0001a 
HIVAN vs Controls OR = 143 (14.8669 - 1375.472) p < 0.0001a OR = 44 (14.46 - 133.8867) p < 0.0001a 
      
nonHIVAN vs HIVnegK OR = 2.693 (0.5492 - 13.1991) p <0.0001a OR = 1.6645 (0.7675 - 3.6099) p =0.1971 
nonHIVAN vs HIVposNK OR = 147 (14.1227 - 1530.0882) p < 0.0001a OR = 14.375 (5.928 - 34.8576) p < 0.0001a 
nonHIVAN vs Controls OR = 182 (17.6173 - 188.2014) p <0.0001a OR = 31.625 (10.7621 - 91.926) p < 0.0001a 
      
HIVnegK vs HIVposNK OR = 54.6 (5.72 - 521.01) p = 0.0005b OR = 8.634 (3.6607 - 20.3748) p < 0.0001a 
HIVnegK vs Controls OR = 67.6 (7.1398 - 640.0436) p = 0.0002b OR = 19 (6.613 - 54.5896) p < 0.0001a 
      
HIVposNK vs Controls OR = 1.2381 (0.073 - 20.9986) p = 0.8224 OR = 2.2 (0.7097 - 6.8776) p =0.1752 
 * represents either 243/272 bp short MNS16A sizes. 
asignificant at p< 0.0001, bsignificant at 0.0001<p<0.001 and csignificant at p < 0.05. 
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Both genotype and allele distributions did not differ significantly in three CKD groups. Apart 
from allele distributions in HIVAN and HIVnegK groups (p = 0.00453) (table 11). This data also 
shows significant association MNS16A L/L genotype with CKD. The L/L genotype was 
significantly underrepresented in the participants without CKD. Furthermore, comparison of 
allele distributions revealed no significant difference in the groups without CKD. In addition, the 
MNS16A L/L was significantly over represented in the CKD groups (Fig. 23). This further 
supports our suggestion that the MNS16A long allele is significantly associated with CKD 
regardless of HIV status.  
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Figure 23: Distribution of long and short MNS16A alleles between kidney disease and no kidney disease 
groups. There was a significant difference in the distribution of alleles between the two groups (*** = 
p<0.0001). Analysis performed using the GraphPad Prism version 5. 
 
 
 
 
 
65 
 
HIV positive HIV negative
0
20
40
60
80
Long
Short
***  ***
   ***
N
u
m
b
e
r 
o
f 
al
le
le
s
 
Figure 24: Distribution of long and short MNS16A alleles in HIV positive and HIV negative participants. 
There was a significant difference in the distribution of alleles between the two groups (*** = p<0.0001). 
Analysis performed using the GraphPad Prism version 5. 
These findings indicate that the long MNS16A allele is significantly associated with kidney 
disease and HIV positive status. Although that seems to be the case, the long allele seems to 
occur mostly in CKD participants regardless of HIV status (Fig. 24).  
3.8. MNS16A Sequencing 
Sequencing of the MNS16A PCR products was performed to identify the variant sequences. 
More than 50 individuals were sequenced and sequences were compared to the human 
genome sequence Dec 2013 (GRCh38/hg38) through UCSC genome browser (accessed 12 
August 2014). A BLAST search of the MNS16A sequence using previously designed (Wang et al., 
2003) primers resulted in a 302 bp fragment with 100% homology the hTERT sequence 
(NG_009265.1 www.ncbi.nlm.nih.gov). Figure 25 shows the different sizes and position of the 
MNS16A variant. 
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Figure 25: Alignment of MNS16A successful sequences showing the 274 and 243 bp sizes in different patient samples. The vertical lines show the 
missing repeats within the 243 bp size variant of the MNS16A. (*Reference sequence chr5: 1252360-1252651 GRCh37/hg19).  
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Section 3:  Telomere length. 
3.9. Relative telomere length (RTL) analysis 
Relative telomere length (RTL) was analysed by qPCR as described earlier in the methods 
section 2.3.4.1. We examined the relationship between relative telomere length and MNS16A 
size with participant age, gender as well as HIV status. Only 20 DNA samples were used per 
histopathology group due to limited and poor quality DNA obtained from Formalin-fixed, 
paraffin-embedded (FFPE) kidney biopsies. Figure 26 shows the average RTL in each 
histopathology group. Although there was a statistically significant difference (p<0.05) in the 
average RTL between all the different histopathology groups, the HIVAN and HIV positive 
without kidney disease participants presented with noticeably shorter RTL.   
*p = 0.012
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Figure 26: Graph showing the average RTL per histopathology group. The HIVAN and HIV positive 
without kidney disease groups presented with the lowest RTL. The healthy individuals (controls) 
presented with longer RTL. 
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3.9.1. Correlation of RTL with MNS16A variants 
There was no significant association between minisatellite size and relative telomere length 
(RTL) (p>0.05). However, participants with L/S* genotype had relatively shorter telomere length 
compared to participants with the L/L and S*/S* MNS16A genotype (Fig. 27). Kruskal-Wallis test 
comparing the median RTL in different CKD groups revealed no significant association (Fig. 27) 
with MNS16A  genotype.   
 
 
Figure 27: Graph representing the mean relative telomere length in participants with different MNS16A 
genotypes. DEL represents DNA samples suggested to have a deletion within the MNS16A chromosomal 
position in the primers lie.  
 
 
 
 
 
 
p = 0.2441 
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Table 12: Dunns multiple comparisons test for RTL versus MNS16A genotype in different individuals. No 
statistically significant difference in the RTL per group.  
Dunn's Multiple Comparison Test Difference in rank sum Significant when p < 
0.05 
HIVAN vs NONHIVAN -6.625 p>0.05 
HIVAN vs HIV NEG CKD -4.250 p>0.05 
HIVAN vs HIV POS no CKD -1.750 p>0.05 
HIVAN vs CONTROLS 2.000 p>0.05 
NONHIVAN vs HIV NEG CKD 2.375 p>0.05 
NONHIVAN vs HIV POS no CKD 4.875 p>0.05 
NONHIVAN vs CONTROLS 8.625 p>0.05 
HIV NEG CKD vs HIV POS no CKD 2.500 p>0.05 
HIV NEG CKD vs CONTROLS 6.250 p>0.05 
HIV POS no CKD vs CONTROLS 3.750 p>0.05 
 
There was no statistically significant association between MNS16A genotype and RTL. 
Furthermore, there was no statistically significant difference in RTL between the five 
histopathology groups (Table 12). It should be noted that CKD participants with L/L MNS16A 
genotype presented with slightly longer telomere length compared to CKD individuals with L/S* 
and S*/S* genotypes. The participants in this group with the L/L genotype revealed relatively 
longer telomeres compared to other genotypes. This trend is consistent with the findings of 
Concetti and colleagues (2013). Even so, this needs to be validated with larger sample sizes.  
3.9.2. Correlation of RTL with age 
Several studies have analysed telomeres in relation to ageing. In this study, participants RTLs 
were grouped according to their different age ranges. Furthermore, RTL was correlated with 
age in the presence and absence of CKD. This revealed that telomere length is generally 
associated with ageing (Fig. 28). Again, this finding is coherent with known progressive 
telomere shortening and its association with ageing. The findings are not significant. This may 
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be due to the small sample size (n = 100) used for RTL analysis which further requires validation 
with larger sample sizes. 
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Figure 28: Correlation of relative telomere length and age in individuals with CKD regardless of HIV status. A) HIVAN, B) nonHIVAN, C) HIV 
negative CKD , D) HIV positive no CKD and E) HIV negative no CKD (Controls). Most of the HIVAN participants presented with shorter RTL (below 
2) compared to other groups. 
(r = -0.2333, n = 20, p>0.05) (r = -0.4356, n = 20, p>0.05) 
(r = 0.1622, n = 20, p>0.05) 
(r = -0.3234, n = 20, p>0.05) (r = -0.152, n = 20, p>0.05) 
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There was no significant correlation between age and relative telomere length (ns = p > 0.05 at 
95% CI) within all the histopathology groups. In figure 28, individuals with the severe form of 
CKD i.e. HIVAN displayed on average shorter relative telomere length compared to other 
histopathology groups. Indeed a similar trend is observed in histopathology groups where 
younger individuals present with relatively longer telomere length with exceptions in the HIV 
negative with CKD group.  
Spearman’s correlation test was used to determine the relationship between RTL and age. Since 
telomere length is inversely proportional to age, a negative association was expected. All 
histopathology groups presented with a non-significant (p>0.05) weak negative correlation 
except for the HIV negative with CKD group, of which had a weak positive correlation (i.e. 
suggests telomere length increases with age. There are many factors that influence telomere 
length in different individuals. These factors include diet, exercise, economic status and viral 
infection (i.e. HIV). The above mentioned factors could partly explain the disparities in relative 
telomere length observed in the study group. Furthermore, no data regarding diet and lifestyle 
of study participants was recorded and hence data analysis was only restricted to available 
information. 
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3.9.3. Correlation of RTL with HIV status 
A statistically significant association of HIV status with RTL was observed. However, shown also 
in figure 29 is HIV positive individuals presenting with generally shorter telomere length 
compared to HIV negative individuals in absence/presence of CKD. Further analysis using Dunns 
multiple comparison test revealed no significant difference in RTL in participants with CKD (Fig. 
29).  
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Figure 29: Correlation of RTL with HIV status. The green represents participants with CKD and the red 
represents participants without CKD. The HIV positive individuals presented with shorter RTL compared 
to HIV negative individuals, regardless of CKD status. 
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Chapter 4: Discussion 
The current study was designed to elucidate the genetic variation in telomere biology related 
genes and their regulatory elements in a black South African cohort. In addition to identifying 
the variation, we also investigated the potential role of telomere dynamics in CKD. The 
objectives included using bioinformatics tools and literature to uncover the variation in 
telomere maintenance genes in different populations. To understand the molecular basis of 
diseases, studies are using genome wide association data to identify single nucleotide 
polymorphisms (SNPs) that either increase disease risk and/or affect drug metabolism (Agrawal 
et al., 2012; Shay, 2003; Shay and Wright, 2002). Telomere biology has been shown to play 
major roles in genome stability. It is well documented that during genome instability, some 
telomere-related genes are dysregulated. In this light, telomere biology is widely accepted as a 
biomarker of disease risk and possibly progression. Variation within telomere biology genes has 
been shown to confer risk to several diseases including ageing syndromes and cancer. In 
addition, telomere length and the consequence of telomere shortening varies among different 
individuals. Moreover, the genetic determinants of telomere length apart from paternal age are 
poorly understood.  Therefore others have sort out to identify the possible variation within 
telomere associated genes.  
Of the several telomere-related genes, hTERT is one of the most highly conserved with minimal 
variation across species and across populations. It is the hTERT, hTERC and the Shelterin 
associated genes that have been shown to display variation that increase disease risk and affect 
telomere length. This study sort out to investigate the variation within the hTERT gene, a gene 
that encodes for the protein that catalyses telomere elongation is involved in cell proliferation, 
cell signalling  and viability.  hTERT was the target gene in these analyses as it is one of the well-
studied genes whose dysregulation has been implicated in several diseases. hTERT has been 
further suggested to be a critical role player in CKD. It has been suggested that hTERT provides 
terminally differentiated podocytes with unlimited proliferative potential resulting in 
glomerular collapse (Shkreli et al., 2012). The genetic elements that govern the expression of 
this particular gene have become an interesting area of research. Some of these regulatory 
elements such as the hTERT promoter and MNS16A have come up as notable. 
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The discussion that follows explores the implications of each finding. Firstly evidence of 
differences and similarities in distribution of common variant alleles in the hTERT gene and 
promoter. The lack of association studies in African populations in particular those in the 
telomere biology field. In addition, we report an association of MNS16A with CKD in the black 
South African cohort in this study. It should be noted that several studies have assessed the role 
of hTERT polymorphisms including promoter and MNS16A in many diseases. However no study 
has to date assessed the role of hTERT promoter and MNS16A in CKD. This is the first  report to 
our knowledge that demonstrates an association of MNS16A with CKD in a black South African 
cohort. 
4.1. Bioinformatics Data 
Most large population studies done in African populations have been  to explore variation but 
data regarding association of variation with disease susceptibility is limited. 
4.1.1. The hTERT gene 
Several studies have been performed to date to assess the common variants within the hTERT 
gene and their association with disease. It is noteworthy that most of these studies were only 
performed in non-African populations. Numerous variants have been identified within the gene 
and have been associated with cancers and ageing disorders. These include gliomas, lung and 
breast cancers as well as idiopathic pulmonary fibrosis (Mirabello et al., 2010; Pooley et al., 
2010; Qu et al., 2014). The variants within the hTERT gene have been further shown to increase 
risk of cardiovascular disease and ultimately influence telomere length, a major determinant of 
cell life cycle (Blackburn, 2000) 
Several research groups have described associations between the rs2736100 variants and 
cancer risk, however most results were inconclusive of the allele conferring risk (Gago-
Dominguez et al., 2011; Jin et al., 2009; Shen et al., 2010; Wang et al., 2010; Wrensch et al., 
2009). In addition the most of the associations were reported in non-African populations in 
Europe and Asia. Although the variant has been associated with adenocarcinoma risk in African-
Americans (Spitz et al., 2013), a lack of association with breast cancer risk in women of African 
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ancestry was reported (Zheng et al., 2012). This is the only study to date that has assessed the 
role of this particular variant in disease pathogenesis in African ancestry.  
Currently available allele and genotype frequencies accessed through 1000 Genomes and 
HapMap Data, revealed no significant difference in the distribution of the rs2736100 alleles 
across different populations. The African populations genotyped for the SNP were assessed to 
annotate the variant and determine the distribution in different populations. No association 
studies to date have been performed to investigate the role of this particular variant in disease 
susceptibility. Our bioinformatics analyses have shown that there is still missing data on the 
pathogenicity and distribution of some of the hTERT variants some of which are clinically 
important risk alleles in non-African populations.  
Another specific variant within hTERT is rs2736098. This variant has been previously shown to 
confer risk to lung cancer in Asian, African American and European populations, as well as 
bladder cancer in European populations (Mirabello et al., 2009). Even though the variant has 
been shown to have clinical importance in disease susceptibility, there is still limited data on 
the distribution of this rs2736098 in different populations. Most of the association studies were 
performed in Asian populations.  
Similarly, studies have shown that rs401681 is not associated with telomere shortening, breast 
and colorectal cancers or melanoma in Caucasians (Pooley et al., 2010). Furthermore, a study 
revealed association with decreased risk of oesophageal cancer in Chinese individuals (Yin et al., 
2014). In contrast, a meta-analysis revealed that the T allele is associated with increased risk for 
pancreatic cancer in Chinese individuals (Liu et al., 2014).  
4.1.2. The hTERT promoter 
Increased telomerase activity has been identified as one of the hallmarks of disease progression 
and severity in 80-95% of human cancers (Hanahan and Weinberg, 2011; Shay et al., 2001). 
Moreover, the catalytic activity of the telomerase has been shown to be highly dependent on 
the expression of the human telomerase reverse transcriptase (hTERT), a critical component of 
the telomerase enzyme. Gene regulatory regions such as the hTERT promoter and minisatellite 
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(MNS16A) have become important targets for identifying variants that alter hTERT expression. 
The hTERT promoter plays a significant role in regulating hTERT expression as it has been shown 
to influence binding of several transcription factors that regulate hTERT expression (Kyo et al., 
2008).  In recent studies, hTERT promoter mutations have been shown to occur most often in 
melanoma, bladder cancer and hepatocellular carcinoma, and clear cell carcinomas (Hosen et 
al., 2015; Huang et al., 2015; Huang et al., 2013; Nault et al., 2013; Simon et al., 2015).  
These variants include somatic promoter mutations C228T (Chr5:1295228 C>T) and C250T 
(Chr5: 1295250 C>T) which were both identified in human melanomas (Huang et al., 2013). 
Another common variant rs2853669 (Chr5:1295349 T>C) which confers increased risk to several 
types of cancers including gliobastomas, breast cancers and esophageal squamous cell 
carcinoma (ESCC) (Park et al., 2014; Zhao et al., 2014). Furthermore, rs35226131 (Chr5:1295373 
C>T) a promoter variant also associated with ESCC (Zhao et al., 2014). In addition, more recent 
evidence also displays an association of TERT promoter mutations with sinonasal malignant 
melanoma (Jangard et al., 2015) bladder cancer (Li et al., 2015) as well as  primary liver tumors 
(Nault and Zucman-Rossi, 2015). It would be interesting to assess whether these variants are 
associated with any of the above mentioned cancers in South African populations as they have 
not been reported before.  
Some of the common reported variants (C228T and C250T) were not detected in all of the 
populations genotyped in HapMap Project and 1000 genomes. However, the variants 
rs2853669 and rs35226131 were observed in the HapMap populations. There was no significant 
difference in the distribution of rs35226131 alleles within the different HapMap populations. 
Nevertheless, there was a difference observed in distribution of rs2853669 alleles between 
African and non-African populations. In particular the African populations had higher 
frequencies of the minor allele. 
The minor allele C of rs2853669 has been previously associated with several diseases was 
underrepresented in African populations. Data regarding the pathogenicity of this particular 
variant is limited in African populations. However it should be noted that the rs2853669 C/C 
genotype has been associated with lower hTERT expression in French individuals (Labussiere et 
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al., 2014). Among the complex regulation of telomerase expression, rs2853669 has been shown 
to modulate both hTERT expression and impact on prognosis in bladder cancer (Rachakonda et 
al., 2013)and poor outcomes in gliomas (Labussiere et al., 2014).  
None of the common variants or SNPs within the hTERT promoter were detected in the BSO 
population. Low coverage SNP detection application was used in the BSO population. This may 
partly explain failure to detect common promoter variants in BSO population. Out of all the 
known hTERT gene variants, only a small percentage was detected in the BSO population. 
Furthermore, none of the promoter variants were detected.  
The Luhya in Webuye, Kenya (LWK) and Yoruba in Ibadan, Nigeria (YRI) have always been used 
as the gold standard for genotype and allele distribution comparison in the South African black 
population. This is due to the fact that global scale analysis of the BSO reveals homogeneity 
with the two African populations LWK and YRI. According to May and colleagues (2013), these 
two populations appeared to cluster together when analysed using the multiple component 
analysis (MCA). Although LWK and YRI cluster together with BSO on a global scale, May et al 
(2013) discovered significant heterogeneity between the three populations. In addition to this 
observed heterogeneity, our data revealed that the BSO population may also be very similar to 
the ACB population. Furthermore, research into these variants has revealed that different 
populations display diverse distribution of variants. Some of these variants either increase of 
decrease susceptibility to different diseases in different populations.  
4.2. Promoter 
Telomere regulation has become a well-known biomarker of several diseases including ageing 
and cancer (Blackburn, 2005a; Blasco et al., 1999; Letsolo et al., 2010; Shay and Wright, 2001a, 
b; Shay et al., 2001). It has been postulated that regions that regulate expression of the critical 
component of telomerase, the hTERT are very important players in disease susceptibility 
involving dysregulation of hTERT (Counter et al., 1998; Park et al., 2014; Shkreli et al., 2012).  
None of the promoter variants were detected in our study population. This finding suggests 
that the hTERT promoter variants may be tissue/cell specific and thus also not associated with 
CKD, as they were not detected in our study population. However it should be noted that none 
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of the variants were detected in the BSO population either. This implies that these variants are 
regional and population specific. 
4.3. MNS16A 
Regulation of hTERT gene expression through MNS16A has been demonstrated as an important 
role player in transcription (Hofer et al., 2011; Hofer et al., 2013; Wang et al., 2003; Wang et al., 
2008). Here, we are the first group to report MNS16A variation in a self-identified black South 
African population. We provided the evidence that shows significant association of long 
MNS16A allele (302 bp) with chronic kidney disease regardless of HIV status. This particular 
MNS16A variant seems to occur exclusively in participants with CKD. Interestingly, participants 
with CKD and are HIV negative had a higher frequency of the L/S* (* 243 bp or 272 bp) 
compared to all groups. According to the clinical data, HIV infected participants with CKD had 
progressed to the late stages of CKD (stages 3 – 5). Whereas uninfected participants with CKD 
were mostly in the early stages of CKD (stages 1 and 2). This finding suggests that the L/L 
MNS16A genotype may be associated with CKD progression and severity.   
However it should be noted that there has been disparity on the role of the MNS16A in disease 
susceptibility. It has been shown that the MNS16A S* allele has been associated with increased 
risk of developing gliomas, breast and colorectal cancers (Hofer et al., 2011; Wang et al., 2008). 
On the contrary, the MNS16A L allele and L/L genotype were associated with increased risk in 
renal cell carcinomas (RCC), prostate and lung cancers (Hofer et al., 2013; Wang et al., 2003). 
There are no studies to date which have reported MNS16A variation in black South African 
individuals. 
4.4. Relative Telomere Length (RTL) 
Although DNA from blood samples for the no kidney disease group was used, it should be noted 
that telomere length determination has become routine practise (Sanders and Newman, 2013). 
The telomere length in leucocytes is often used as a biomarker of ageing in humans. In addition, 
control participants could not voluntarily donate their biopsies. 
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None of the correlations between RTL and MNS16A genotype, age and CKD status were 
statistically significant, it has been reported that progressive telomere shortening is associated 
with ageing, HIV status (Pathai et al., 2013), MNS16A L/L genotype (Concetti et al., 2013) and 
CKD (D'Agati and Appel, 1997; Pathai et al., 2013). However, mechanisms by that regulate 
telomere length in the presence or absence of disease is still poorly understood. It should be 
noted that although telomere length is largely influenced by age, other environmental factors 
including diet, exercise, viral infections and disease status increase the rate of telomere 
attrition (Lin et al., 2012; Mirabello et al., 2009). 
The role of MNS16A variants in regulation of telomere length is poorly understood. It has been 
suggested that the L/L genotype is associated with progressive telomere shortening in 
individuals in Italy (Concetti et al., 2013). In contrast, no association between MNS16A variant 
sizes and telomere length was discovered in the Han Chinese population (Liu et al., 2014). Our 
study showed relatively shorter telomere length in CKD individuals with L/S* MNS16A genotype 
compared to individuals with L/L and S*/S* MNS16A genotypes in the same group. Additionally, 
CKD individuals displayed relatively longer/stabilised telomere length compared to all the other 
genotyped individuals. Despite that, the data was insignificant due to small sample size used for 
RTL analysis. Furthermore, the L and S* alleles were underrepresented in the no CKD and CKD 
groups respectively.  
Telomere length is recognised as conventional biomarker of ageing (Blackburn, 2000). It is well 
documented that telomere length shortens with age (Chang and Harley, 1995). In a review of in 
vitro and in vivo studies, Martin-Ruiz and colleagues (2005) found that telomere length satisfied 
several criteria as a biomarker of ageing. Telomere length changes with age, has great inter-
individual variability, is linked to basic biology of the cell, and correlates with ageing and ageing-
related disease (Martin-Ruiz et al., 2005). Our findings revealed that although the data analysis 
was not significant, individuals with the severe form of CKD i.e. HIVAN displayed relatively 
shorter telomere length compared to all other individuals in the study. In addition, reduced 
telomere length has been shown to be associated with kidney  (Wills and Schnellmann, 2011) 
and cardiovascular diseases (CVD). Another study investigated the association of telomere 
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length with progression of kidney disease in 132 patients with type 1 diabetes. They found 
that telomere length independently predicted progression to diabetic nephropathy (Wills and 
Schnellmann, 2011).  
In the presence of HIV, telomere attrition has been suggested to progress faster compared to 
HIV uninfected individuals. One study revealed that high level of HIV viral load is associated 
with accelerated telomere attrition (Cote et al., 2012). In our study, a significant association 
was observed between HIV status and RTL. In addition, on close inspection HIV negative 
individuals presented with considerably longer RTL compared to HIV positive individuals 
regardless of age and disease presence. This is consistent with other studies. For example HIV 
infected individuals usually present with shorter telomere length in their leucocytes (Cote et 
al., 2012; Wolthers et al., 1996). Additionally a study in South Africa also reported a strong 
relationship of accelerated telomere length shortening in HIV infected individuals (Pathai et 
al., 2013).  
It is noteworthy that the study had limitations and thus results should be taken with caution 
especially those pertaining to telomere length. This may be due to the sample size used and 
limited DNA availability and quality. Other factors to be considered are the environmental risk 
factors which play a significant role in CKD and telomere shortening. These were not taken into 
consideration as no information regarding the social or economic status, participant diet and 
whether participants suffered from any other disease besides CKD was obtained. All of the fore-
mentioned has been suggested to influence both telomere length and disease progression. 
However, this data strongly demonstrates the association of the minisatellite with disease risk 
in CKD regardless of HIV status. It remains to be seen whether the MNS16A variants play a role 
in telomere length maintenance and hTERT gene expression. 
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Chapter 5: Conclusion 
In conclusion, the findings of this study provide some evidence on the differences in the genetic 
variation of telomere biology genes between different populations. Notable differences in the 
distribution of some hTERT gene and promoter variants in African populations requires further 
investigations on the role of the variation in disease susceptibility.  
This is the first study to report MNS16A stability in black South Africans with CKD in the 
presence and absence of HIV infection. Interestingly, a significant association of MNS16A L 
allele with CKD was detected. Despite the lack of conclusive evidence on the role of the 
MNS16A variation with RTL, data obtained is suggestive of a functional role that MNS16A plays 
in CKD severity and/or progression. Therefore this study has identified a potential role player in 
CKD. Although further investigation is required, this study supports the role of telomere 
dynamics in chronic kidney disease. 
Study limitations and Recommendations 
 
Due to low (DNA and RNA) concentrations and poor quality, telomere length could not be 
determined using a more accurate telomere length detection procedure i.e. STELA. 
Furthermore, RTL could only be determined in 100/159 individuals. Functional studies to 
investigate the potential role of the MNS16A variation in hTERT expression were unsuccessful 
at several trials, as RNA was of poor quality. 
As much as the findings reveal a significant association of MNS16A long allele with CKD, 
validation with larger sample sizes and functional studies to address the role of telomere 
biology in CKD are recommended. This limited data availability warrants further research and 
encourages large scale association studies exploring the role of telomere biology variation and 
disease susceptibility in African populations. Since Africans have high genetic diversity, more 
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regional and ethnicity based research is advised. Furthermore, identification of these variants 
will assist in advancement of diagnostic and therapeutic measures to combat or reduce 
diseases that involve dysregulation of telomere biology genes.  
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8.2. Appendix B: Reagent and Solution preparation 
Primer and probe Dilutions 
Tris – EDTA (TE) buffer pH 7.0: 180 μL 
100 μM primer/probe: 20 μL 
Total of 200 μL of 10 μM primer 
Primers stored at -20 °C. 
Buffer Preparations 
1X Tris-Borate EDTA (TBE) buffer 1X Tris-Acetate EDTA (TAE) buffer 
10X TBE (Sigma): 100 mL 10X TAE (Sigma): 100 mL 
ddH2O: 900 mL ddH2O: 900 mL 
1L of 1X TBE buffer 1L of 1X TAE buffer 
 
Agarose gels 
0.8% Agarose gel (600 mL) 1% Agarose gel (50 mL) 2.5% Agarose gel (50 mL) 
1X TAE/TBE: 600 mL 1X TAE/TBE: 50 mL 1X TAE/TBE: 50 mL 
4.8 g of Agarose (Seakem) 0.5 g of Agarose (Conda) 1.25 g of Agarose (Conda) 
 
Mix the agarose powder with the 1X TAE/TBE buffer. Heat the mixture in the microwave until 
the agarose has completely dissolved. Wait for mixture to cool down and add 2.0 µL of GR-
Green DNA stain per 50 mL of liquid agarose gel. Pour liquid gel on gel casting tray with comb 
already inserted. Leave gel to solidify for 30 – 45 minutes.  
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PCR preparations and conditions:  
 MNS16A and promoter 
Component 1X Final concentration 
Phusion Flash Master Mix (2X) 5 µL 1X 
Forward Primer (10 µL) 0.5 µL 1 µM 
Reverse primer (10 µL) 0.5 µL 1 µM 
Nuclease free water 3 µL - 
Template DNA (50 ng/µL) 1 µL 5 µM 
Total 10 µL   
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8.3. Appendix C: Participant Clinical Data and MNS16A genotypes.  
HIVAN Study IDs. Age  Sex 
MNS16A 
Genotypes Creatinine (µmol/L) Urea (mmol/L) eGFR (ml/min) 
1 HIVAN-01 46 M L/L 540 22.5 10.6 
2 HIVAN-02 34 F L/L 266 12.3 18.9 
3 HIVAN-03 36 F L/L 534 20.4 8.4 
4 HIVAN-04 53 F Del 111 7.6 47.4 
5 HIVAN-05 32 F L/L 799 14.5 5.4 
6 HIVAN-06 27 F L/L 262 8.4 20.2 
7 HIVAN-07 56 F L/L 250 9.2 18.4 
8 HIVAN-08 38 M L/L 186 9.6 37.7 
9 HIVAN-09 30 M L/L n/a n/a n/a 
10 HIVAN-10 29 F L/L 570 25.6 8.1 
11 HIVAN-11 35 F L/L 194 8.5 27.1 
12 HIVAN-12 19 F Del 152 6.9 40.6 
13 HIVAN-13 29 M L/S 869 20.5 6.7 
14 HIVAN-14 36 F L/L 469 26.9 9.7 
15 HIVAN-15 27 M L/L 733 20.4 8.3 
16 HIVAN-16 30 F L/L 419 19 11.5 
17 HIVAN-17 26 F L/L 1511 32 2.7 
18 HIVAN-18 40 M L/L 486 21 12.3 
19 HIVAN-19 31 F L/L 555 16 8.3 
20 HIVAN-21 34 M L/L 312 10.6 21.2 
21 HIVAN-22 40 M L/L n/a n/a n/a 
22 HIVAN-23 32 M L/S 952 14.9 5.9 
23 HIVAN-24 51 F Del n/a n/a n/a 
24 HIVAN-25 32 F Del n/a n/a n/a 
25 HIVAN-26 30 F Del 811 27.8 5.4 
n/a = Not available = Clinical data not provided for those particular participants. 
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HIVAN Study IDs. Age  Sex 
MNS16A 
Genotypes Creatinine (µmol/L) Urea (mmol/L) eGFR (ml/min) 
26 HIVAN-27 27 M L/S 523 12.6 12.2 
27 HIVAN-28 37 M L/L 285 13 23.1 
28 HIVAN-29 49 M S/S n/a n/a n/a 
29 HIVAN-30 27 F S/S 624 20.5 7.4 
30 HIVAN-31 26 F L/S 975 30 4.5 
31 HIVAN-32 27 F L/L 1963 30.4 2 
32 HIVAN-33 24 M L/L 648 15.4 9.8 
33 HIVAN-34 38 M L/L 915 18.5 6 
34 HIVAN-35 32 F Del n/a n/a n/a 
35 HIVAN-37 23 F S/S 154 5.7 38.5 
36 HIVAN-38 33 F S/S 243 7 21.1 
n/a = Not available = Clinical data not provided for those particular participants. 
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nonHIVAN 
Study IDs. Diagnosis 
Age 
(yrs) Sex 
MNS16A 
genotypes 
Creatinine 
(µmol/L) 
Urea 
(mmol/L) 
eGFR 
(ml/min) 
1 
nonHIVAN-
01 FSGS 30 F 
L/L n/a n/a n/a 
2 
nonHIVAN-
02 IgA Nephropathy 29 M 
L/S 485 29.2 13.2 
3 
nonHIVAN-
03 FSGS 37 F 
L/L 106 4 53.8 
4 
nonHIVAN-
04 FSGS 34 F 
L/L 388 16.7 12.2 
5 
nonHIVAN-
05 FSGS 29 M 
L/L 279 22.2 17.9 
6 
nonHIVAN-
06 HIVICK 52 F 
L/L 232 14 30.8 
7 
nonHIVAN-
07 Minimal Change disease 38 M 
DEL 39 2.9 228.5 
8 
nonHIVAN-
08 Diabetic Nephropathy 38 F 
L/L 659 27.4 6.5 
9 
nonHIVAN-
10 HIVICK 27 M 
L/L 46 3.4 150.2 
10 
nonHIVAN-
11 Mebranoproliferative glomerulonephritis I 30 F 
L/L n/a n/a n/a 
11 
nonHIVAN-
12 HIVICK 29 M 
L/L n/a n/a n/a 
12 
nonHIVAN-
13 Benign nephrolosclerosis 41 M 
L/S n/a n/a n/a 
 
 
105 
 
n/a = Not available = Clinical data not provided for those particular participants. 
 
 
13 
nonHIVAN-
14 Membranous glomerulonephritis 30 F 
L/L 68 6 93.7 
14 
nonHIVAN-
15 
Global glomerulosclerosis with ischemic changes 
c/w ANS 31 F 
L/L 692 18.7 6.4 
15 
nonHIVAN-
16 FSGS 31 M 
L/L 135 n/a 56.8 
16 
nonHIVAN-
17 FSGS 48 F 
L/S n/a n/a n/a 
17 
nonHIVAN-
18 HIVICK 41 F 
L/S 234 13.6 21.1 
18 
nonHIVAN-
19 HIVICK 27 F 
L/L n/a n/a n/a 
19 
nonHIVAN-
20 Membranous glomerulonephritis 37 M 
L/L n/a n/a n/a 
20 
nonHIVAN-
21 HIVICK 30 F 
L/S n/a n/a n/a 
21 
nonHIVAN-
28 FSGS 31 M 
S/S 227 13 31.2 
22 
nonHIVAN-
29 HIVICK 26 F 
L/L 618 22 7.6 
23 
nonHIVAN-
33 Membranous glomerulonephritis 50 M 
L/L n/a n/a n/a 
24 
nonHIVAN-
34 Membranous glomerulonephritis 47 F 
DEL n/a n/a n/a 
25 
nonHIVAN-
35 FSGS 34 F 
L/L 380 25 12.5 
 
 
106 
 
 
 
nonHIVAN Study IDs. Diagnosis 
Age 
(yrs) Sex 
MNS16A 
genotypes 
Creatinine 
(µmol/L) 
Urea 
(mmol/L) 
eGFR 
(ml/min) 
26 nonHIVAN-36 FSGS 36 M DEL n/a n/a n/a 
27 nonHIVAN-37 Membranous glomerulonephritis 19 F DEL n/a n/a n/a 
28 nonHIVAN-38 FSGS 25 M S/S n/a n/a n/a 
29 nonHIVAN-39 Thrombotic microangiopathy 54 M L/L n/a n/a n/a 
30 nonHIVAN-40 Membranous glomerulonephritis 39 F L/L n/a n/a n/a 
31 nonHIVAN-41 
Global glomerulosclerosis-low grade 
IgAN 66 F 
L/L 105 16.2 48.3 
32 nonHIVAN-42 HIVICK 32 F S/S 153 8.5 36.3 
n/a = Not available = Clinical data not provided for those particular participants. 
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HIV Negative with Kidney 
Disease Study IDs. 
Diagnosis 
Age 
(yrs) 
Sex 
MNS16A 
genotypes 
Creatinine 
(µmol/L) 
Urea 
(mmol/L) 
eGFR 
(ml/min) 
1 HIV_neg-01 IgA Nephropathy 39 M L/L n/a n/a n/a 
2 HIV_neg-02 Membranous glomerulonephritis 57 M L/L n/a n/a n/a 
3 HIV_neg-03 FSGS 30 M L/L 6.4 21.9 1929.9 
4 HIV_neg-04 Nodular Glomerulosclerosis 30 F L/S 860 36 5 
5 HIV_neg-05 Lupus nephritis 34 M L/S n/a n/a n/a 
6 HIV_neg-06 Global glomerulosclerosis 33 M L/S n/a n/a n/a 
7 HIV_neg-07 Lupus nephritis 26 F L/S 92 2 68 
8 HIV_neg-08 FSGS 43 F S/S n/a n/a n/a 
9 HIV_neg-09 Membranous glomerulonephritis 39 M L/S n/a n/a n/a 
10 HIV_neg-10 
Membranoproliferative 
Glomerulonephritis I 31 M L/S n/a n/a n/a 
11 HIV_neg-11 Membranous glomerulonephritis 18 F L/S 18 5.2 481.6 
12 HIV_neg-12 Membranous glomerulonephritis 35 M S/S 115 5.9 66.7 
13 HIV_neg-13 Lupus nephritis 44 F L/L n/a n/a n/a 
14 HIV_neg-14 Benign Nephrolesclerosis 27 F S/S 2047 39.1 1.9 
15 HIV_neg-15 Minimal change disease 38 F L/L 50 5.3 127.3 
16 HIV_neg-17 Diabetic Nephropathy 57 M L/S 89 8.3 81.2 
17 HIV_neg-18 FSGS 27 M L/L 104 5.9 79 
18 HIV_neg-19 Membranous glomerulonephritis 61 F L/S 316 100 13.8 
19 HIV_neg-21 Global glomerulosclerosis 32 F L/S 977 22 4.3 
20 HIV_neg-22 Membranous glomerulonephritis 35 F L/S 36 1.5 189.1 
21 HIV_neg-25 Acute tubular necrosis (Not a CKD) 61 F S/S 52 5.8 110.5 
22 HIV_neg-26 Thrombotic microangiopathy 24 M L/L 168 18.7 168 
23 HIV_neg-28 Minimal change disease 21 M S/S 152 13.9 53.6 
24 HIV_neg-31 
Extensive GS, hilar SS could be 
Oxalate (Oxalosis) 48 M L/L n/a n/a n/a 
25 HIV_neg-36 Membranous glomerulonephritis 45 M L/L 78 5 99.2 
         n/a = Not available = Clinical data not provided for those particular participants. 
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HIV-Pos Without Kidney 
Disease Study IDs. 
Age 
(yrs) 
Sex MNS16A genotypes Creatinine (µmol/L) Urea (mmol/L) eGFR (ml/min) 
1 HIV_Pos-01 39 F S/S 74 n/a 80.5 
2 HIV_Pos-05 41 F L/L 1274 n/a 3 
3 HIV_Pos-06 31 F S/S 51 n/a 129.7 
4 HIV_Pos-15 45 F L/S 76 n/a 75.9 
5 HIV_Pos-16 33 F L/S 66 n/a 95.1 
6 HIV_Pos-17 60 F S/S 62 n/a 90.5 
7 HIV_Pos-18 47 M S/S 88 n/a 85.6 
8 HIV_Pos-19 45 F L/S 84 n/a 67.6 
9 HIV_Pos-27 27 F S/S 41 n/a 171.6 
10 HIV_Pos-28 38 F S/S 72 n/a 83.6 
11 HIV_Pos-29 26 F L/S 53 n/a 128.5 
12 HIV_Pos-30 46 M S/S 77 n/a 100.3 
13 HIV_Pos-31 44 M S/S 78 n/a 99.7 
14 HIV_Pos-32 39 M S/S 142 n/a 51.2 
15 HIV_Pos-33 32 M S/S 65 n/a 131.2 
16 HIV_Pos-34 42 F S/S 52 n/a 119.2 
17 HIV_Pos-40 35 M S/S 92 n/a 86.3 
18 HIV_Pos-41 32 F S/S 53 n/a 123.2 
19 HIV_Pos-42 31 F S/S 46 n/a 146.1 
20 HIV_Pos-43 34 F S/S 73 n/a 84.1 
21 HIV_Pos-44 33 F S/S 55 n/a 117.4 
22 HIV_Pos-45 43 F S/S 49 n/a 127.1 
23 HIV_Pos-46 42 F del 73 n/a 80.6 
24 HIV_Pos-47 31 F S/S 62 n/a 103.5 
25 HIV_Pos-48 40 F L/S 78 n/a 75.4 
n/a = Not available = Clinical data not provided for those particular participants. 
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HIV-Pos Without Kidney 
Disease Study IDs. 
Age 
(yrs) 
Sex MNS16A genotypes 
Creatinine 
(µmol/L) 
Urea (mmol/L) eGFR (ml/min) 
26 HIV_Pos-49 24 F S/S 66 n/a 101.4 
27 HIV_Pos-50 38 F L/S 70 n/a 86.3 
28 HIV_Pos-51 21 M L/S 60 n/a 156.8 
29 HIV_Pos-52 40 F S/S 72 n/a 82.7 
30 HIV_Pos-53 45 M S/S 88 n/a 86.3 
31 HIV_Pos-54 42 F L/S 71 n/a 83.2 
        n/a = Not available = Clinical data not provided for those particular participants.
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Human Population Controls Study IDs. 
Age 
(yrs) 
Gender MNS16A Genotypes  
1 HPC-01 39 M S/S 
2 HPC-02 57 M S/S 
3 HPC-03 30 F S/S 
4 HPC-04 30 F S/S 
5 HPC-05 34 M S/S 
6 HPC-06 33 M S/S 
7 HPC-07 26 F S/S 
8 HPC-08 43 F S/S 
9 HPC-09 39 F S/S 
10 HPC-11 18 F S/S 
11 HPC-12 35 M L/L 
12 HPC-13 44 F L/S 
13 HPC-14 27 F S/S 
14 HPC-15 38 M S/S 
15 HPC-16 26 F S/S 
16 HPC-17 57 M S/S 
17 HPC-18 27 F S/S 
18 HPC-19 61 F S/S 
19 HPC-20 21 F S/S 
20 HPC-21 32 F S/S 
21 HPC-22 35 M S/S 
22 HPC-23 28 M S/S 
23 HPC-24 37 M S/S 
24 HPC-25 61 F S/S 
25 HPC-26 24 M S/S 
26 HPC-35 37 F L/S 
27 HPC-36 36 M S/S 
28 HPC-37 31 F S/S 
29 HPC-38 41 F L/S 
30 HPC-39 31 M S/S 
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8.4. Appendix D: The genotype frequencies of the hTERT gene and promoter 
variants in different populations. 
Number  
hTERT variants detected in the BSO population (n = 94) 
Chr. SNP 
Allele 
1 
Allele 
2 
Homozygous 
Allele 1  Heterozygous  
Homozygous 
Allele 2 MISSING 
1 5 rs5031049 A G 0 5 89 0 
2 5 rs2736122 T C 6 36 52 0 
3 5 rs2736118 A G 12 42 40 0 
4 5 rs11133715 A G 4 30 60 0 
5 5 rs35412024 C T 2 4 88 0 
6 5 rs4246742 T A 9 35 50 0 
7 5 rs33988305 T C 0 8 86 0 
8 5 rs34002187 A G 0 8 86 0 
9 5 rs11133719 T C 0 8 86 0 
10 5 rs4975605 A C 13 44 37 0 
11 5 rs56345976 A G 8 44 41 1 
12 5 rs114500100 C A 0 8 86 0 
13 5 rs10069690 C T 11 44 39 0 
14 5 rs7734992 T C 7 43 44 0 
15 5 rs34471035 A G 1 11 82 0 
16 5 rs13167280 A G 0 12 82 0 
17 5 rs6866456 C T 9 42 43 0 
18 5 rs7725218 A G 17 48 29 0 
19 5 rs35809415 A G 0 7 87 0 
20 5 rs2736100 G T 22 46 26 0 
21 5 rs2853677 G A 11 39 44 0 
22 5 rs2736099 A G 4 30 60 0 
23 5 rs2853676 T C 12 42 40 0 
24 5 rs2853672 A C 19 51 24 0 
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Number  
hTERT variants detected in the CEU population (n = 99) 
Chr. SNP 
Allele 
1 
Allele 
2 
Homozygous Allele 
1  Heterozygous  
Homozygous Allele 
2 MISSING 
1 5 5:1253744 A G 2 29 68 0 
2 5 5:1255520 A G 1 26 72 0 
3 5 5:1256585 A G 7 38 54 0 
4 5 5:1257288 T C 0 19 80 0 
5 5 5:1257621 A G 6 41 52 0 
6 5 5:1259489 T C 0 13 86 0 
7 5 5:1260195 C T 6 42 51 0 
8 5 5:1261051 T C 0 7 92 0 
9 5 5:1261052 A G 12 43 44 0 
10 5 5:1264068 T C 6 41 52 0 
11 5 5:1264152 G A 7 41 51 0 
12 5 5:1265204 T C 6 42 51 0 
13 5 5:1265373 A G 6 41 52 0 
14 5 5:1265935 A G 6 41 52 0 
15 5 5:1266226 C T 6 42 51 0 
16 5 5:1266310 A G 12 51 36 0 
17 5 5:1267202 G C 1 19 79 0 
18 5 5:1267356 A T 2 27 70 0 
19 5 5:1270983 G C 2 33 64 0 
20 5 5:1271524 T C 5 31 63 0 
21 5 5:1271661 C T 6 35 58 0 
22 5 5:1273610 T G 8 29 62 0 
23 5 5:1273905 A G 16 54 29 0 
24 5 5:1275528 A C 21 51 27 0 
25 5 5:1275857 C T 2 25 72 0 
26 5 5:1276772 C A 6 47 46 0 
27 5 5:1276785 T C 23 51 25 0 
28 5 5:1276794 A C 23 51 25 0 
29 5 5:1276873 G A 18 49 32 0 
30 5 5:1277577 G A 22 54 23 0 
31 5 5:1278584 T C 2 19 78 0 
32 5 5:1279224 G T 0 12 87 0 
33 5 5:1279790 T C 5 46 48 0 
34 5 5:1279964 C G 15 51 33 0 
35 5 5:1280028 A G 3 33 63 0 
36 5 5:1280128 C T 19 50 30 0 
37 5 5:1280477 A G 2 21 76 0 
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38 5 5:1280830 C G 11 51 37 0 
39 5 5:1280938 G A 15 51 33 0 
40 5 5:1282319 A C 11 42 46 0 
 
 
hTERT variants detected in the CHB population (n = 103) 
Number Chr. SNP 
Allele 
1 
Allele 
2 
Homozygous Allele 
1  
Heterozygous  
Homozygous Allele 
2 
MISSING 
1 5 5:1255520 A G 4 29 70 0 
2 5 5:1256585 A G 1 15 87 0 
3 5 5:1257288 T C 6 35 62 0 
4 5 5:1257621 A G 1 15 87 0 
5 5 5:1260195 C T 1 17 85 0 
6 5 5:1260957 T C 0 4 99 0 
7 5 5:1266226 C T 1 18 84 0 
8 5 5:1266310 G A 3 32 68 0 
9 5 5:1267202 G C 18 41 44 0 
10 5 5:1267356 A T 15 44 44 0 
11 5 5:1270983 G C 0 7 96 0 
12 5 5:1271524 T C 2 20 81 0 
13 5 5:1271661 T C 4 25 74 0 
14 5 5:1273610 G T 19 45 39 0 
15 5 5:1273896 A C 0 0 103 0 
16 5 5:1273905 A G 1 19 83 0 
17 5 5:1283312 A G 12 63 28 0 
18 5 5:1283755 T C 1 36 66 0 
19 5 5:1284135 T C 11 62 30 0 
20 5 5:1284717 T C 5 25 73 0 
21 5 5:1285162 C T 12 66 25 0 
22 5 5:1285974 A C 12 61 30 0 
23 5 5:1287194 G A 12 56 35 0 
24 5 5:1287340 A G 15 57 31 0 
25 5 5:1287505 T C 0 15 88 0 
26 5 5:1288547 T C 3 22 78 0 
27 5 5:1289975 A C 0 15 88 0 
28 5 5:1291293 G A 0 11 92 0 
29 5 5:1291717 C T 7 71 25 0 
30 5 5:1291718 A G 7 71 25 0 
31 5 5:1291720 T C 7 71 25 0 
 
 
115 
 
32 5 5:1291735 G A 0 40 63 0 
33 5 5:1291740 G T 0 40 63 0 
34 5 5:1292983 C A 19 61 23 0 
35 5 5:1294086 T C 13 57 33 0 
 
 
hTERT variants detected in the LWK population (n = 101) 
Number Chr. SNP 
Allele 
1 
Allele 
2 
Homozygous Allele 1  Heterozygous  Homozygous Allele 2 MISSING 
1 5 5:1253744 A G 14 50 37 0 
2 5 5:1254247 G C 11 35 55 0 
3 5 5:1254251 T C 10 36 55 0 
4 5 5:1254451 C T 10 36 55 0 
5 5 5:1254943 T C 10 36 55 0 
6 5 5:1255622 C T 11 31 59 0 
7 5 5:1256228 C T 9 33 59 0 
8 5 5:1256238 C A 0 0 101 0 
9 5 5:1256256 C T 1 6 94 0 
10 5 5:1256585 A G 12 46 43 0 
11 5 5:1257024 T C 4 29 68 0 
12 5 5:1257621 A G 9 45 47 0 
13 5 5:1257905 T C 3 29 69 0 
14 5 5:1259963 A G 3 28 70 0 
15 5 5:1260033 C T 16 34 51 0 
16 5 5:1260195 T C 14 40 47 0 
17 5 5:1261052 A G 5 27 69 0 
18 5 5:1264068 T C 9 45 47 0 
19 5 5:1264143 T C 8 33 60 0 
20 5 5:1264152 A G 17 41 43 0 
21 5 5:1264156 A G 8 34 59 0 
22 5 5:1264163 C T 8 34 59 0 
23 5 5:1265204 C T 17 45 39 0 
24 5 5:1265373 A G 9 45 47 0 
25 5 5:1265664 T C 13 33 55 0 
26 5 5:1265853 T C 0 12 89 0 
27 5 5:1265935 A G 9 44 48 0 
28 5 5:1266226 T C 16 49 36 0 
29 5 5:1266310 G A 19 49 33 0 
30 5 5:1266929 G C 1 23 77 0 
31 5 5:1267202 G C 1 21 79 0 
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32 5 5:1267356 A T 12 45 44 0 
33 5 5:1267497 A G 1 17 83 0 
34 5 5:1267676 A G 1 20 80 0 
35 5 5:1267973 C T 1 10 90 0 
36 5 5:1268464 G A 2 38 61 0 
37 5 5:1268847 C A 2 38 61 0 
38 5 5:1268944 A T 2 31 68 0 
39 5 5:1269365 A G 3 38 60 0 
40 5 5:1270983 G C 19 40 42 0 
hTERT variants detected in the LWK population (n = 101) 
Number Chr. SNP 
Allele 
1 
Allele 
2 
Homozygous Allele 
1  
Heterozygous  
Homozygous Allele 
2 
MISSING 
41 5 5:1271661 C T 19 49 33 0 
42 5 5:1271714 C T 2 39 60 0 
43 5 5:1271861 A G 0 20 81 0 
44 5 5:1271879 A G 1 19 81 0 
45 5 5:1273610 T G 7 35 59 0 
46 5 5:1273905 A G 6 40 55 0 
47 5 5:1274983 G T 2 18 81 0 
48 5 5:1275528 A C 23 53 25 0 
49 5 5:1275857 C T 5 36 60 0 
50 5 5:1276772 C A 3 22 76 0 
51 5 5:1276785 T C 2 25 74 0 
52 5 5:1276788 G A 0 0 101 0 
53 5 5:1276794 A C 2 25 74 0 
54 5 5:1276873 A G 3 34 64 0 
55 5 5:1277577 A G 4 37 60 0 
56 5 5:1279790 C T 10 50 41 0 
57 5 5:1279964 G C 15 45 41 0 
58 5 5:1280022 C T 4 26 71 0 
59 5 5:1280028 A G 3 28 70 0 
60 5 5:1280128 T C 8 45 48 0 
61 5 5:1280252 A G 0 11 90 0 
62 5 5:1280830 C G 4 38 59 0 
63 5 5:1280938 A G 10 44 47 0 
64 5 5:1281079 A G 2 21 78 0 
65 5 5:1281693 C T 18 50 33 0 
66 5 5:1281743 T C 2 18 81 0 
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67 5 5:1281890 C T 18 48 35 0 
68 5 5:1281975 C G 18 50 33 0 
69 5 5:1282159 C T 6 30 65 0 
70 5 5:1282165 C T 6 31 64 0 
hTERT variants detected in the LWK population (n = 101) 
Number Chr. SNP 
Allele 
1 
Allele 
2 
Homozygous Allele 
1  
Heterozygous  
Homozygous Allele 
2 
MISSING 
71 5 5:1282194 T C 1 17 83 0 
72 5 5:1282319 A C 4 40 57 0 
73 5 5:1282414 A G 28 42 31 0 
74 5 5:1283095 T C 1 12 88 0 
75 5 5:1283312 A G 28 44 29 0 
76 5 5:1283755 T C 1 40 60 0 
77 5 5:1283841 A C 8 33 60 0 
78 5 5:1284046 T C 8 33 60 0 
79 5 5:1284135 T C 3 44 54 0 
80 5 5:1284976 T C 1 25 75 0 
81 5 5:1285162 T C 6 46 49 0 
82 5 5:1285238 A G 6 18 77 0 
83 5 5:1285974 A C 3 40 58 0 
84 5 5:1286516 C A 22 51 28 0 
85 5 5:1287194 G A 11 46 44 0 
86 5 5:1287340 A G 3 33 65 0 
87 5 5:1288547 T C 5 42 54 0 
88 5 5:1291293 G A 6 27 68 0 
89 5 5:1291717 C T 12 72 17 0 
90 5 5:1291718 A G 12 72 17 0 
91 5 5:1291720 T C 12 72 17 0 
92 5 5:1291735 G A 0 28 73 0 
93 5 5:1291740 G T 0 28 73 0 
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94 5 5:1292446 T C 1 26 74 0 
95 5 5:1292649 G C 1 26 74 0 
96 5 5:1292714 C G 0 6 95 0 
97 5 5:1292983 A C 24 52 25 0 
